<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006080</article-id><article-id pub-id-type="pmc">PMC11859825</article-id><article-id pub-id-type="doi">10.3390/ph18020268</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00268</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Discovery of Sphingosine Kinase Inhibition by Modified Quinoline-5,8-Diones</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9457-0802</contrib-id><name><surname>Kruschel</surname><given-names>Ryan D.</given-names></name><xref rid="af1-pharmaceuticals-18-00268" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Malone</surname><given-names>Kyle</given-names></name><xref rid="af2-pharmaceuticals-18-00268" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-5031-1033</contrib-id><name><surname>Walsh</surname><given-names>Alison N.</given-names></name><xref rid="af1-pharmaceuticals-18-00268" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6078-0027</contrib-id><name><surname>Waeber</surname><given-names>Christian</given-names></name><xref rid="af2-pharmaceuticals-18-00268" ref-type="aff">2</xref><xref rid="af3-pharmaceuticals-18-00268" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5837-1638</contrib-id><name><surname>McCarthy</surname><given-names>Florence O.</given-names></name><xref rid="af1-pharmaceuticals-18-00268" ref-type="aff">1</xref><xref rid="c1-pharmaceuticals-18-00268" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Artese</surname><given-names>Anna</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00268"><label>1</label>School of Chemistry and ABCRF, University College Cork, Western Road, T12K8AF Cork, Ireland; <email>111380606@umail.ucc.ie</email> (R.D.K.); </aff><aff id="af2-pharmaceuticals-18-00268"><label>2</label>School of Pharmacy, University College Cork, Pharmacy Building, College Road, T12K8AF Cork, Ireland; <email>kylem8414@gmail.com</email> (K.M.); <email>c.waeber@ucc.ie</email> (C.W.)</aff><aff id="af3-pharmaceuticals-18-00268"><label>3</label>Department of Pharmacology and Therapeutics, School of Medicine, University College Cork, T12XF62 Cork, Ireland</aff><author-notes><corresp id="c1-pharmaceuticals-18-00268"><label>*</label>Correspondence: <email>f.mccarthy@ucc.ie</email>; Tel.: +353-21-4901695</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>268</elocation-id><history><date date-type="received"><day>13</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>31</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background:</bold> Sphingosine kinase (SphK) overexpression is observed in many cancers, including breast, renal and leukaemia, which leads to increased cellular proliferation, survival and growth. SphK inhibition has been an attractive target for anticancer drug development for the past decade, with SphK inhibitors such as PF-543 and opaganib exhibiting clinical antitumour effects. By exploiting both CB5468139 and PF-543 as structural leads, we hereby report on the first quinoline-5,8-dione-based SphK inhibitor using a fragment-based approach. <bold>Methods:</bold> The quinoline-5,8-dione framework was developed to incorporate two defined regions, namely a polar quinoline core, which links to an aryl lipophilic chain. All synthetic molecules were characterized by NMR and HRMS and assayed against SphK 1 and 2, and molecular docking studies were performed. A subset of compounds was screened for anticancer activity. <bold>Results:</bold> As the binding site of SphK accommodates the lipophilic tail of sphingosine, we initially set out to explore the substitution of the C(7) aryl moiety to attain eight novel C(7) ether-linked quinoline-5,8-diones, which were screened for SphK1 and SphK2 activity with good potency identified. To improve SphK binding, structural fragments were adapted from PF-543 to participate in hydrogen bonding within the binding site of SphK1. A model study was performed to yield novel compounds through activated C(2) formyl intermediates. Two pyrrolidine-based quinoline-5,8-diones were assayed for SphK activity, with <bold>21</bold> revealing an improvement of SphK1 binding efficacy relative to the parent compound and <bold>20</bold> (and its precursor <bold>4</bold>). Molecular modelling on the pyrrolidine quinoline-5,8-dione construct revealed favourable docking, low binding energies and opportunities for further improvement. <bold>Conclusions:</bold> Although the screening of anticancer activity was inconclusive, low micromolar dual SphK1/2 inhibition with the quinoline-5,8-dione framework has been identified for the first time, and a plausible new binding mode has been identified.</p></abstract><kwd-group><kwd>sphingosine kinase</kwd><kwd>quinoline-5,8-dione</kwd><kwd>fragment-based design</kwd><kwd>kinase inhibition</kwd><kwd>cancer</kwd></kwd-group><funding-group><award-group><funding-source>Government of Ireland Postgraduate Scholarships</funding-source><award-id>GOIPG/2015/3148</award-id><award-id>GOIPG/2017/431</award-id></award-group><award-group><funding-source>SFI-funded infrastructure ProSpect</funding-source><award-id>15/RI/3221</award-id></award-group><award-group><funding-source>FaNS</funding-source><award-id>21/RI/9705</award-id></award-group><funding-statement>R.D.K. and K.M. were supported by the Irish Research Council through Government of Ireland Postgraduate Scholarships (R.D.K: GOIPG/2015/3148; K.M.: GOIPG/2017/431). The authors would like to acknowledge SFI-funded infrastructure ProSpect (15/RI/3221) and FaNS (21/RI/9705).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00268"><title>1. Introduction</title><p>Sphingosine kinase (SphK) upregulation is observed in many cancers, including breast, renal, prostate and leukaemia [<xref rid="B1-pharmaceuticals-18-00268" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceuticals-18-00268" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceuticals-18-00268" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-18-00268" ref-type="bibr">4</xref>]. SphK catalyses the phosphorylation of ceramide-derived sphingosine to sphingosine-1-phosphate (S1P), a biologically active lipid mediator [<xref rid="B5-pharmaceuticals-18-00268" ref-type="bibr">5</xref>]. Two isoforms of SphK exist, SphK1 and SphK2, which catalyse the same chemical transformation but differ in their respective subcellular localization, biochemical properties and biological function [<xref rid="B6-pharmaceuticals-18-00268" ref-type="bibr">6</xref>]. S1P has an important role in regulating cell growth, survival and migration and has been implicated in diseases such as cancer, Alzheimer&#x02019;s disease, pulmonary hypertension and multiple sclerosis [<xref rid="B7-pharmaceuticals-18-00268" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceuticals-18-00268" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceuticals-18-00268" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-18-00268" ref-type="bibr">10</xref>]. In cancer cells, an increase in intracellular S1P is observed by an upregulation of SphK, triggering an increase in cellular growth, survival and migration. It is proposed that the inhibition of SphK would cease S1P production and increase pro-apoptotic ceramide production through a process known as the S1P/ceramide rheostat, a well-documented equilibrium that exists between the two lipids [<xref rid="B11-pharmaceuticals-18-00268" ref-type="bibr">11</xref>]. siRNA-mediated knockdown of SphK expression inhibits proliferation and increases ceramide levels to cause apoptosis of neuroblastoma tumour cell lines [<xref rid="B12-pharmaceuticals-18-00268" ref-type="bibr">12</xref>].</p><p>Early drug development targeted SphK1 for oncology purposes (<xref rid="pharmaceuticals-18-00268-f001" ref-type="fig">Figure 1</xref>); however, further studies have shown that both isoforms are involved in regulating cancer cell processes [<xref rid="B2-pharmaceuticals-18-00268" ref-type="bibr">2</xref>,<xref rid="B13-pharmaceuticals-18-00268" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceuticals-18-00268" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceuticals-18-00268" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceuticals-18-00268" ref-type="bibr">16</xref>]. PF-543 is the most potent SphK1-specific inhibitor reported to date (Ki = 3.6 nM) (<xref rid="pharmaceuticals-18-00268-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B1-pharmaceuticals-18-00268" ref-type="bibr">1</xref>]. Like many potent SphK inhibitors, its structure is based on endogenous sphingosine, namely a polar headgroup, linker and lipophilic tail [<xref rid="B11-pharmaceuticals-18-00268" ref-type="bibr">11</xref>]. This is clearly seen in <xref rid="pharmaceuticals-18-00268-f001" ref-type="fig">Figure 1</xref>, which highlights the polar headgroup, linking group and lipophilic tail common to the majority of SphK inhibitors.</p><p>The selective SphK1 inhibitor PF-543 exhibits cytotoxic effects on both colorectal cancer cells and head and neck squamous cell carcinoma (SCC) [<xref rid="B17-pharmaceuticals-18-00268" ref-type="bibr">17</xref>]. Colorectal cancer cell lines HCT-116, HT-29 and DLD-1 all exhibited necrosis once treated with PF-543 (10 &#x003bc;M), albeit when used at 2.5&#x02013;10-fold higher concentrations than required for S1P reduction in cells. Interestingly, the HT-29 colorectal cancer cell line, which expresses the highest SphK1 levels, was more vulnerable to PF-543 treatment than DLD-1, which has the lowest SphK1 expression. Long-term in vivo studies on HCT-116 tumour-presenting mice administered PF-543 resulted in tumour shrinkage and longer survival with no apparent toxicity observed [<xref rid="B18-pharmaceuticals-18-00268" ref-type="bibr">18</xref>]. SCC cell treatment with PF-543 (25 &#x003bc;M) decreased the proportion of viable cells in a time- and dose-dependent manner. PF-543 is thought to induce cell autophagy, apoptosis and necrosis, with evidence of all three confirmed using flow cytometry. Interestingly, the addition of the ROS scavenger <italic toggle="yes">N</italic>-acetyl-L-cysteine reduced the cytotoxic effects of PF-543 on SCC cells, with necrotic SCC cells induced by PF-543 decreased from 48.6% to 26.3% [<xref rid="B19-pharmaceuticals-18-00268" ref-type="bibr">19</xref>].</p><p>SphK2 is also a well-established anticancer target, with the SphK2 inhibitor opaganib (ABC294640, K<sub>i</sub> = 9.8 &#x003bc;M) successfully reaching phase 2 clinical trials for prostate cancer (<xref rid="pharmaceuticals-18-00268-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B20-pharmaceuticals-18-00268" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceuticals-18-00268" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-18-00268" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceuticals-18-00268" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceuticals-18-00268" ref-type="bibr">24</xref>]. Though no crystal structure currently exists of SphK2, opaganib acts as a competitive inhibitor relative to sphingosine and is predicted to bind in the lipid-binding site [<xref rid="B21-pharmaceuticals-18-00268" ref-type="bibr">21</xref>]. Interestingly, the related compound ABC294735, incorporating a change in the <italic toggle="yes">N</italic>-substituent, is identified as a dual SphK1/2 inhibitor [<xref rid="B22-pharmaceuticals-18-00268" ref-type="bibr">22</xref>].</p><p>In the analysis of SphK inhibitors, the majority conform structurally to sphingosine, with a high degree of lipophilicity and flexibility to aid in binding in the narrow lipid-binding pocket of SphK [<xref rid="B1-pharmaceuticals-18-00268" ref-type="bibr">1</xref>,<xref rid="B25-pharmaceuticals-18-00268" ref-type="bibr">25</xref>]. Recent studies with a number of isoform-selective SphK1 and SphK2 inhibitors have not clinically outperformed PF-543 and opaganib, so there is merit in further exploration of the model [<xref rid="B22-pharmaceuticals-18-00268" ref-type="bibr">22</xref>]. In identifying SphK inhibitors with clinical benefit, the dual SphK1/2 inhibitor safingol has been effective in combination with cisplatin in Phase 1 clinical trials against glioma [<xref rid="B26-pharmaceuticals-18-00268" ref-type="bibr">26</xref>]. In addition, another dual SphK1/2 inhibitor, SKI-II, has been identified to be effective in combination with temolozomide at sublethal doses in glioblastoma cell lines [<xref rid="B27-pharmaceuticals-18-00268" ref-type="bibr">27</xref>].</p><p>Looking at other reported SphK inhibitors, there are a number of compounds that incorporate a quinone. The quinone-based SphK inhibitor CB5468139 was first identified in 2012 by screening the Chembridge Diverset collection for SphK1 inhibitors (<xref rid="pharmaceuticals-18-00268-f002" ref-type="fig">Figure 2</xref>). CB5468139 exhibited high potency towards SphK1 (Ki = 0.3 &#x000b5;M) without affecting SphK2 activity up to 100 &#x000b5;M [<xref rid="B28-pharmaceuticals-18-00268" ref-type="bibr">28</xref>]. Moderate cytotoxicity is reported with the reduced proliferation of A498 kidney adenocarcinoma cells (EC<sub>50</sub> = 10&#x02013;15 &#x003bc;M). However, since CB5468139 has been reported to inhibit multiple kinases, including Met, MST2 and CLK1 (suggesting it is not selective for SphK1), it is difficult to define whether its effect on cells is due to on or off SphK target interactions [<xref rid="B1-pharmaceuticals-18-00268" ref-type="bibr">1</xref>]. Another quinone, F-12509A, was isolated from the fungus <italic toggle="yes">Trichopezizella barbata</italic> and identified very early as an SphK inhibitor and fits the polar/linker/lipophilic framework with the potential for covalent/irreversible activity [<xref rid="B29-pharmaceuticals-18-00268" ref-type="bibr">29</xref>].</p><p>Our approach to developing new inhibitors of SphK sees quinoline-5,8-dione as a key fragment analogous to the naphthoquinone-based CB5468139. It is a known pharmacophore in NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibition capable of redox cycling in vivo and can result in the oxidation of critical amino acids in targeted enzymes [<xref rid="B30-pharmaceuticals-18-00268" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-18-00268" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceuticals-18-00268" ref-type="bibr">32</xref>]. Our initial premise is to exploit the structural relationship between naphthoquinone-based CB5468139 and quinoline-5,8-dione (<xref rid="pharmaceuticals-18-00268-f003" ref-type="fig">Figure 3</xref>) to generate a polar pyridine and quinone central quinoline-5,8-dione core and an ether-connected lipophilic tail. We set out to install lipophilic aryl moieties to fill the space of the cyclohexane ring and to probe the lipophilic binding site of SphK. The activity of novel quinoline-5,8-diones was screened for SphK inhibition, followed by anticancer activity to test the viability of the framework as an anticancer agent. We hereby report the development of a new framework for SphK inhibition.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-18-00268"><title>2. Results and Discussion</title><sec id="sec2dot1-pharmaceuticals-18-00268"><title>2.1. Development of the Quinoline-5,8-Dione Intermediate</title><p>Our initial premise exploits the structural relationship between naphthoquinone-based CB5468139 and quinoline-5,8-dione (<xref rid="pharmaceuticals-18-00268-f003" ref-type="fig">Figure 3</xref>). It was proposed that the replacement of the tertiary amine of CB5468139 would allow the exploration of new chemical space with an ether linker to a lipophilic tail analogous to that of PF-543. The synthetic approach adopted utilised a two-step route to successfully furnish 7-bromo-quinoline-5,8-dione <bold>3</bold> in 70% overall yield (<xref rid="pharmaceuticals-18-00268-sch001" ref-type="fig">Scheme 1</xref>) [<xref rid="B33-pharmaceuticals-18-00268" ref-type="bibr">33</xref>]. This approach is favoured as the quinone moiety is installed from the outset, removing the need to oxidise post-substitution (which, on scoping the transformation, proved problematic). Literature precedence suggests that the presence of the C(7) bromine can be exploited to guide the chemical transformation [<xref rid="B34-pharmaceuticals-18-00268" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceuticals-18-00268" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceuticals-18-00268" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceuticals-18-00268" ref-type="bibr">37</xref>]. In addition, the presence of the 2-methyl group can be probed as a chemical handle.</p></sec><sec id="sec2dot2-pharmaceuticals-18-00268"><title>2.2. Synthetic Route to 7-Phenoxy Quinoline-5,8-Diones</title><p>The synthesis of the target framework commences from 7-bromo-quinoline-5,8-dione <bold>3</bold> (<xref rid="pharmaceuticals-18-00268-sch001" ref-type="fig">Scheme 1</xref>) [<xref rid="B32-pharmaceuticals-18-00268" ref-type="bibr">32</xref>]. The lipophilic tail can be installed in the core by employing a robust and facile chemoselective displacement of the C(7) bromine using a range of phenols (<xref rid="pharmaceuticals-18-00268-sch002" ref-type="fig">Scheme 2</xref>). The incorporation of substrate lipophilicity is well understood to increase molecular interactions, and our primary screen incorporated phenols, including halogen substitution, to probe the lipid-binding site of SphK [<xref rid="B38-pharmaceuticals-18-00268" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceuticals-18-00268" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceuticals-18-00268" ref-type="bibr">40</xref>]. The displacement of bromide with the requisite phenoxide led to the formation of nine novel quinoline-5,8-dione analogues [<xref rid="B36-pharmaceuticals-18-00268" ref-type="bibr">36</xref>]. This reaction proceeded under ambient conditions with variable yields (7&#x02013;84%). It is noteworthy that a <italic toggle="yes">meta</italic>-chloro substituent on the phenol moiety resulted in a reduced yield of <bold>8</bold> (19%) and <bold>10</bold> (7%).</p></sec><sec id="sec2dot3-pharmaceuticals-18-00268"><title>2.3. Screening of Quinoline-5,8-Diones for Sphingosine Kinase Inhibition</title><p>Preliminary sphingosine kinase inhibition screening was performed on eight analogues (<bold>4</bold>&#x02013;<bold>11</bold>), incorporating PF-543 and opaganib as reference SphK1 and SphK2 inhibitors, respectively. The fluorescence-based assay involved incubating the quinoline-5,8-diones with SphK isoforms individually (recombinant SphK1 and SphK2 in duplicate) [<xref rid="B41-pharmaceuticals-18-00268" ref-type="bibr">41</xref>]. The inhibitory activity (percentage of positive control) of the compounds against both SphK isoforms is illustrated in <xref rid="pharmaceuticals-18-00268-f004" ref-type="fig">Figure 4</xref> (see fluorescence data in <xref rid="app1-pharmaceuticals-18-00268" ref-type="app">Supplementary Materials, Tables S2&#x02013;S5</xref>). With respect to the inhibitory references, PF-543 was tested at a 100 nM concentration (within its reported inhibitory range) and, as expected, exhibited high SphK1 selectivity with 63% inhibition; Opaganib at 10 &#x000b5;M exhibited high SphK2 selectivity and 36% inhibition (reference Ki = 9.8 &#x003bc;M) [<xref rid="B19-pharmaceuticals-18-00268" ref-type="bibr">19</xref>,<xref rid="B22-pharmaceuticals-18-00268" ref-type="bibr">22</xref>]. The investigational quinoline-5,8-diones were tested at a 10 &#x003bc;M concentration, with all but one of our initial panels exhibiting the inhibition of SphK1 and SphK2 with as high as 69% inhibition at the 10 &#x003bc;M concentration. The majority of compounds yielded dual effects on SphK1 and SphK2, with compounds <bold>5</bold>&#x02013;<bold>7</bold> and <bold>9</bold> equipotent against both isoforms. The <italic toggle="yes">para</italic>-F <bold>6</bold> and <italic toggle="yes">para</italic>-CN <bold>7</bold> were the best dual inhibitors, both exhibiting &#x02265; 54% inhibition against SphK1 and &#x02265; 56% against SphK2. The <italic toggle="yes">para</italic>-methoxy derivative <bold>4</bold> exhibited a level of selectivity for SphK1 (and compounds <bold>8</bold> and <bold>11</bold> against SphK2, albeit at lower potency). Increasing the lipophilicity via the addition of two halogens to the aryl moiety to yield <bold>8</bold>, <bold>9</bold> and <bold>10</bold> surprisingly resulted in a reduction in SphK1 inhibition (26%, 20% and 0%, respectively), so increasing lipophilicity does not improve binding. Highlighting this, <italic toggle="yes">para</italic>-F and <italic toggle="yes">meta</italic>-Cl <bold>10</bold> exhibited 0% inhibition against both isoforms. <italic toggle="yes">Para</italic>-hydroxyethyl <bold>11</bold> is identified to have good potency and signals that there is room for substitution and, indeed, H-bonding groups in the binding orientation of this compound class. There does not appear to be a linear relationship between the electronic effects of Cl, F, OMe and CN and binding. However, the performance of compounds <bold>4</bold>&#x02013;<bold>8</bold> signalled further potential, and we set out to probe whether improved potency and selectivity could be achieved.</p></sec><sec id="sec2dot4-pharmaceuticals-18-00268"><title>2.4. Extension of the Quinoline-5,8-Dione Framework to Target SphK1 Inhibition</title><p>Encouraged by the identification of SphK inhibition using an entirely novel compound library, a modelling approach was adopted to improve SphK1 inhibition of the quinoline-5,8-dione framework. Kim et al. reported that alteration to the linker aromatic region of PF-543 could result in more cytotoxic analogues, and, indeed, many others have identified chemical space within the binding pocket [<xref rid="B42-pharmaceuticals-18-00268" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-18-00268" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceuticals-18-00268" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceuticals-18-00268" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceuticals-18-00268" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceuticals-18-00268" ref-type="bibr">47</xref>]. Similar to sphingosine (<xref rid="pharmaceuticals-18-00268-f005" ref-type="fig">Figure 5</xref>A), the flexibility of PF-543 allows it to feed down the narrow &#x02018;J-channel&#x02019; of SphK1, as illustrated in <xref rid="pharmaceuticals-18-00268-f005" ref-type="fig">Figure 5</xref>B. SphK1 selectivity of PF543 originates from the structural difference in the ligand-binding site between SphK1 and SphK2. The lipid-binding sites of SphK1 and SphK2 differ by only three amino acid residues at positions 374, 260 and 358; SphK1 has Phe, Ile and Met and SphK2 has Cys, Val and Leu in the respective positions [<xref rid="B48-pharmaceuticals-18-00268" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceuticals-18-00268" ref-type="bibr">49</xref>]. The structural differences result in a larger binding site in SphK2 [<xref rid="B50-pharmaceuticals-18-00268" ref-type="bibr">50</xref>].</p><p>In addition to the multiple hydrophobic interactions observed throughout the &#x02018;J-channel&#x02019; of SphK1, one key formal hydrogen bond interaction is observed between Asp264 and the pyrrolidine hydroxyl group [<xref rid="B48-pharmaceuticals-18-00268" ref-type="bibr">48</xref>]. Thus, we undertook the incorporation of a D-prolinol fragment at the 2-position of quinoline to probe the effect on SphK1 binding (<xref rid="pharmaceuticals-18-00268-sch003" ref-type="fig">Scheme 3</xref>). This has the effect of extending the polar headgroup from the pyridine (as in opaganib) towards that of an SphK1 selective inhibitor, PF-543. The pyrrolidone headgroup offers known hydrogen-bonding interactions within the lipid-binding site of SphK1, and thus, a synthetic route was designed in the quinoline-5,8-dione framework to improve SphK1 inhibition potency [<xref rid="B1-pharmaceuticals-18-00268" ref-type="bibr">1</xref>,<xref rid="B49-pharmaceuticals-18-00268" ref-type="bibr">49</xref>].</p></sec><sec id="sec2dot5-pharmaceuticals-18-00268"><title>2.5. Synthesis of the Quinoline-5,8-Dione Framework to Target SphK1 Inhibition</title><p>The C(2) methyl group offers a useful chemical handle, employing selenium dioxide as an oxidant. A similar oxidative approach is utilised to functionalise the unreactive C(2) position of methyl quinoline-5,8-dione precursors to the anticancer agent Lavendamycin [<xref rid="B51-pharmaceuticals-18-00268" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceuticals-18-00268" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceuticals-18-00268" ref-type="bibr">53</xref>]. A selection of seven phenyl ether quinoline-5,8-diones from <xref rid="pharmaceuticals-18-00268-sch002" ref-type="fig">Scheme 2</xref> was chosen (<bold>4</bold>&#x02013;<bold>9</bold>), and, in addition, the 4-bromo analogue <bold>12</bold> was included (<bold>12</bold> was prepared as in <xref rid="pharmaceuticals-18-00268-sch002" ref-type="fig">Scheme 2</xref> in 66%). The oxidation of the C(2) position proceeded with variable isolated yields (27&#x02013;91%, <xref rid="pharmaceuticals-18-00268-sch004" ref-type="fig">Scheme 4</xref>).</p><p>The oxidation of nitrile <bold>7</bold> was unsuccessful after multiple attempts (the aldehyde product <bold>16</bold> was identified on NMR analysis, but the complex product mixture was inseparable using chromatographic techniques). Five of the aldehyde products (<bold>13</bold>&#x02013;<bold>15</bold>, <bold>18</bold>&#x02013;<bold>19</bold>) were chosen for screening against sphingosine kinases, and there was a noticeable drop in inhibition, with activity only evident in the <italic toggle="yes">para</italic>-methoxy <bold>13</bold> and <italic toggle="yes">para</italic>-fluoro <bold>15</bold> derivatives (<xref rid="pharmaceuticals-18-00268-f006" ref-type="fig">Figure 6</xref>). Subsequent efforts progressed with these two aldehydes for reductive amination to form the pyrrolidine.</p><p>D-Prolinol was reacted with the formyl group of <bold>13</bold> and <bold>15</bold> through a reductive amination to furnish the pyrrolidine headgroup [<xref rid="B54-pharmaceuticals-18-00268" ref-type="bibr">54</xref>]. The products <bold>20</bold> and <bold>21</bold> were isolated as colourless oils in moderate yields (37&#x02013;38%) (<xref rid="pharmaceuticals-18-00268-sch005" ref-type="fig">Scheme 5</xref>).</p><p>Both <bold>20</bold> and <bold>21</bold> are directly related to the most potent SphK inhibitors identified from preliminary screening (<bold>4</bold> and <bold>6</bold>) and were screened for SphK inhibitory activity (<xref rid="pharmaceuticals-18-00268-f006" ref-type="fig">Figure 6</xref>). <italic toggle="yes">Para</italic>-Fluoro <bold>21</bold> exhibited an improvement in SphK1 inhibition potency (70%) with a slight reduction in SphK2 inhibition potency (43%) relative to the parent compound <bold>6</bold> (54% and 60%, respectively). Conversely, <bold>20</bold> exhibits better inhibition of SphK2 (82% vs. 37% for precursor <bold>4</bold>) and slightly worse for SphK1 (63% vs. 69% for <bold>4</bold>).</p><p>In order to confirm the activity against SphKs, we next conducted an IC<sub>50</sub> assay against SphK1 and SphK2. Two related compounds were chosen for this, <bold>4</bold> and <bold>20</bold>, which both possess the <italic toggle="yes">para</italic>-OMe phenol and differ at the 2-position, with <bold>4</bold> containing the lipophilic methyl and <bold>20</bold> the hydrophilic pyrrolidine (<xref rid="pharmaceuticals-18-00268-f007" ref-type="fig">Figure 7</xref>). Compound <bold>4</bold> is identified with an IC<sub>50</sub> of 30 and 8 &#x000b5;M against Sphk1 and SphK2, respectively (and <bold>20</bold> with values of 42 and 13 &#x000b5;M, respectively). It is interesting to note that upon incorporation of the pyrrolidine, no significant benefit is identified over the starting methyl substituent.</p><p>In summary, synthesis of a new panel of 2- and 7-substituted quinoline-5,8-diones is reported for the first time, which exhibits dual sphingosine kinase inhibition at clinically relevant concentrations.</p></sec><sec id="sec2dot6-pharmaceuticals-18-00268"><title>2.6. Molecular Model of the Quinoline-5,8-Dione Framework in SphK1</title><p>Given the promising results, docking simulations for the SphK1 model were performed to identify predicted binding poses for SphK1 inhibitors in the series. Docking simulations were calculated using the CLC Drug Discovery Workbench 3.0, which utilises the docking scoring function PLANTS<sub>PLP</sub> [<xref rid="B55-pharmaceuticals-18-00268" ref-type="bibr">55</xref>]. A crystal structure of PF-543 exists docked within the active site of SphK1 (PDB ID: 4V24), and this protein was selected for docking [<xref rid="B48-pharmaceuticals-18-00268" ref-type="bibr">48</xref>].</p><p>Pyrrolidine quinoline-5,8-dione <bold>21</bold> and precursor <bold>6</bold> were chosen as potent and consistent SphK1 inhibitors and docked into the lipid-binding site of SphK1, with PF-543 providing a comparison docking score. The docked PF-543 ligand exhibited a score of &#x02212;109.2 (<xref rid="pharmaceuticals-18-00268-t001" ref-type="table">Table 1</xref>). The addition of the pyrrolidone headgroup derived from the SphK1 selective inhibitor PF-543 improved the predicted docking score from &#x02212;56.5 for <bold>6</bold> to &#x02212;82.7 for <bold>21</bold>. A decrease in lipophilicity from PF-543 to <bold>21</bold> is also evident.</p><p>Further investigation into the binding pose of <bold>21</bold> suggests that the orientation of the pyrrolidine headgroup of <bold>21</bold> adopts a reversed orientation relative to PF-543 (<xref rid="pharmaceuticals-18-00268-f008" ref-type="fig">Figure 8</xref>A,C,D). Unlike PF-543, which forms one hydrogen bond interaction with Asp264, <bold>21</bold> is predicted to engage in two hydrogen bonds with Ala360 and His397 located near the bottom &#x02018;toe&#x02019; of the &#x02018;J-channel&#x02019; (<xref rid="pharmaceuticals-18-00268-f008" ref-type="fig">Figure 8</xref>A,B). Multiple hydrophobic interactions were observed throughout the &#x02018;J-channel&#x02019;, many of which are shared with PF-543, including the Met358 &#x003c0;-sulfur interaction, the Leu405 alkyl interaction, the Ile260 &#x003c0;-alkyl interaction and the Val263 &#x003c0;-alkyl interaction.</p><p>While the binding pose of <bold>21</bold> is unusual, it is worth noting that this predicted model is in agreement with the in vitro SphK1 inhibition (<xref rid="pharmaceuticals-18-00268-f004" ref-type="fig">Figure 4</xref>), with the most potent inhibition observed from the <italic toggle="yes">para</italic>-substituted <bold>4</bold>, <bold>6</bold> and <bold>7</bold> moieties, which do not possess significant steric influence. Substituents in the <italic toggle="yes">meta</italic> position, or both the <italic toggle="yes">para</italic> and <italic toggle="yes">meta</italic> positions, would naturally result in poor SphK1 binding. Thus, preliminary modelling studies suggest that the pyrrolidine quinoline-5,8-dione framework can bind readily with the active site of SphK1 in silico, with promising hydrogen bonding interactions. There is an overlap with the bioassay data, and further hydrogen-bonding accepting regions are identified near the fluorine, which will be the scope of future work. Looking at <xref rid="pharmaceuticals-18-00268-f001" ref-type="fig">Figure 1</xref>, this is an area of SphK that has not been targeted to date (components in red lack any terminal polar functionality) and is the focus of our current work.</p></sec><sec id="sec2dot7-pharmaceuticals-18-00268"><title>2.7. Anticancer Screening of Quinoline-5,8-Diones</title><p>A preliminary anticancer study was conducted through the National Cancer Institute 60 human tumour cell line panel (NCI60) on a representative selection of the aryl-ether quinoline-5,8-diones (<xref rid="pharmaceuticals-18-00268-t002" ref-type="table">Table 2</xref>) [<xref rid="B57-pharmaceuticals-18-00268" ref-type="bibr">57</xref>]. Disappointingly, the mean cell percentage growth at a 10 &#x000b5;M concentration across the human cancer cell lines revealed no promising anticancer activity, with values ranging from 84&#x02013;97% growth. In order to frame this, although PF-543 and opaganib have well-known anticancer activity, only opaganib has been assessed through the NCI cancer-screening platform (NSC796101) and is associated with a mean GI<sub>50</sub> across 60 cell lines of 11.5 &#x003bc;M. While not unexpected, as active SphK inhibitors under clinical investigation are used in conjugation with a cytotoxic adjuvant therapy, there is further work necessary to improve potency and cellular activity.</p><p>It is worth noting that <italic toggle="yes">para</italic>-Br and -F analogues <bold>6</bold> and <bold>12</bold> exhibited specific activity against NCI-H522 (lung), ACHN (renal) and MDA-MB-468 (breast) cancer cell lines. For example, cell growths of &#x02212;44% and &#x02212;27% at 10 a &#x000b5;M concentration were recorded against the stage-two adenocarcinoma NSCLC cell line NCI-H522, which is sensitive to oxidative stress [<xref rid="B58-pharmaceuticals-18-00268" ref-type="bibr">58</xref>]. This may merit further investigation into the mechanisms of action.</p></sec></sec><sec id="sec3-pharmaceuticals-18-00268"><title>3. Materials and Methods</title><sec sec-type="methods" id="sec3dot1-pharmaceuticals-18-00268"><title>3.1. Materials, Reagents and General Experimental Procedures</title><p>All solvents were distilled prior to use by the following methods: dichloromethane was distilled from phosphorus pentoxide, ethyl acetate was distilled from potassium carbonate and hexane was distilled prior to use. Organic phases were dried over anhydrous magnesium sulfate. All commercial reagents were procured from both international and local suppliers such as Fluorochem (Glossop, UK), Thermo Scientific (Dublin, Ireland) and Merck (Arklow, Ireland) and were used without further purification unless stated otherwise. Furthermore, 1H (300 MHz) and 13C (75 MHz) NMR spectra were recorded on a Bruker (Coventry, UK) Avance 300, 400 or 600 NMR spectrometer. All spectra were recorded at 20 &#x000b0;C in deuterated dimethylsulfoxide (DMSO-<italic toggle="yes">d<sub>6</sub></italic>) or deuterated chloroform (CDCl<sub>3</sub>) using tetramethylsilane (TMS) as an internal standard unless otherwise stated. Chemical shifts (&#x003b4;H and &#x003b4;C) are reported in parts per million (ppm) relative to the reference peak. The order of citation in parentheses is (a) the number of protons, (b) multiplicity and (c) coupling constants (coupling constants (<italic toggle="yes">J</italic>) are reported in Hertz (Hz)). Infrared spectra were recorded as thin films on sodium chloride plates for oils or as potassium bromide (KBr) discs for solids on a Perkin Elmer (Dublin, Ireland) Spectrum 100 FT-IR spectrometer or a Perkin Elmer (Dublin, Ireland) Spectrum One FT-IR spectrometer. Nominal mass spectra were recorded on a Waters (Manchester, UK) Quattro Micro triple quadrupole spectrometer (QAA1202) in ESI mode using 50% acetonitrile&#x02013;water containing 0.1% formic acid as eluent. High-resolution mass spectra (HRMS) were recorded on a Waters (Manchester, UK) LCT Premier Time-of-Flight spectrometer (KD160) or a Waters (Manchester, UK) Vion IMS mass spectrometer (SAA055 K) in ESI mode using 50% acetonitrile&#x02013;water containing 0.1% formic acid as eluent. Samples (max. 1 mg) were dissolved in acetonitrile, water or 10% DMSO/acetonitrile. Melting points were measured on a uni-melt Thomas Hoover capillary melting point apparatus and were uncorrected. Thin-layer chromatography (TLC) was carried out on precoated silica gel plates (Merck 60 PF254). Visualisation was achieved by UV light detection (254 and 366 nm). Wet flash column chromatography was performed using Merck PF254 silica gel unless otherwise stated. The purity of each compound (&#x0003e;95%) was identified by LCMS.</p></sec><sec id="sec3dot2-pharmaceuticals-18-00268"><title>3.2. Chemical Synthesis</title><sec id="sec3dot2dot1-pharmaceuticals-18-00268"><title>3.2.1. 5,7-Dibromo-2-methylquinolin-8-ol (<bold>2</bold>)</title><p>8-Hydroxyquinaldine <bold>1</bold> (6.02 g, 37.8 mmol) was dissolved in acetonitrile (200 mL) with stirring at room temperature. <italic toggle="yes">N</italic>-Bromosuccinimide (12.17 g, 68.4 mmol) was added portionwise. The mixture was stirred for 5 min, at which point a white precipitate was observed. Additional acetonitrile was added (200 mL), and the reaction mixture was allowed to stir for a further 1 h. The precipitate was isolated via suction filtration and washed with ice-cold acetonitrile (100 mL) to remove residual traces of succinimide. The sample was oven-dried at 80 &#x000b0;C, yielding the product as a light pink fluffy solid, which was used without further purification: <bold>2</bold> (9.89 g, 83%). m.p. 99.0&#x02013;100.0 &#x000b0;C (lit. 126.9&#x02013;128.5 &#x000b0;C) [<xref rid="B33-pharmaceuticals-18-00268" ref-type="bibr">33</xref>]; &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 2849, 2478, 1584, 1490, 1430, 1367, 1329, 1313, 1248, 1195, 1144, 932, 869, 736; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 2.76 (s, 3H), 7.41 (d, <italic toggle="yes">J</italic> = 8.6 Hz, 1H), 7.81 (s, 1H), 8.29 (d, <italic toggle="yes">J</italic> = 8.6 Hz, 1H); <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI-): 314.0 (M-H)<sup>&#x02212;</sup>, 40%, 316.0 (M-H)<sup>&#x02212;</sup>, 100%, 318.0 (M-H)<sup>&#x02212;</sup>, 40%.</p></sec><sec id="sec3dot2dot2-pharmaceuticals-18-00268"><title>3.2.2. 7-Bromo-2-methylquinoline-5,8-dione (<bold>3</bold>)</title><p>5,7-Dibromo-2-methylquinolin-8-ol <bold>2</bold> (1.48 g, 4.67 mmol) was dissolved portionwise in concentrated sulfuric acid (95&#x02013;97%, 8.0 mL) with stirring, producing a yellow solution. The mixture was cooled to 0 &#x000b0;C using an ice bath. Nitric acid (65%, 0.90 mL, 14.0 mmol) was added dropwise over 1 min, producing a ruby red colour. The reaction was stirred for a further 30 min. After stirring, the reaction mixture was added to ice water (100 mL), resulting in a yellow solution. The product was extracted with dichloromethane (3 &#x000d7; 30 mL), washed with water (30 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding the product as a pale orange solid, which was used without further purification: <bold>3</bold> (0.98 g, 84%). m.p. 150.0&#x02013;152.0 &#x000b0;C (decomp.) (lit. 178.0 &#x000b0;C) [<xref rid="B59-pharmaceuticals-18-00268" ref-type="bibr">59</xref>]; &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3045, 1685, 1656, 1581, 1429, 1386, 1310, 1280, 1129, 1104, 910, 847, 802, 711, 610; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 2.79 (s, 3H), 7.55 (s, 1H), 7.57 (d, <italic toggle="yes">J</italic> = 8.1 Hz, 1H), 8.29 (d, <italic toggle="yes">J</italic> = 8.1 Hz, 1H); <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 252.1 (M+H)<sup>+</sup>, 95%, 254.1 (M+H)<sup>+</sup>, 100%.</p></sec><sec id="sec3dot2dot3-pharmaceuticals-18-00268"><title>3.2.3. 7-(4-Methoxyphenoxy)-2-methyl-6,7-dihydroquinoline-5,8-dione (<bold>4</bold>)</title><p>Potassium carbonate (0.895 g, 6.47 mmol) and 4-methoxyphenol (0.251 g, 2.02 mmol) were added to dimethylformamide (10 mL) and stirred at room temperature for 10 min. 7-Bromo-2-methylquinoline-5,8-dione <bold>3</bold> (0.497 g, 1.97 mmol) was then charged, resulting in a dark brown suspension. The reaction mixture was then stirred for a further 2 h and poured over ice water (100 mL), forming a brown precipitate. The crude product was extracted with ethyl acetate (3 &#x000d7; 50 mL). The combined organic layers were washed with saturated sodium sulfite (3 &#x000d7; 50 mL) and brine (2 &#x000d7; 50 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a crude dark orange solid. Flash column chromatography was performed on this crude material (1:0 Hexane:Ethyl acetate&#x02014;1:1 Hexane:Ethyl acetate), yielding the pure product as an orange solid: <bold>4</bold> (0.487 g, 84%) (Rf: 0.4, Hexane-Ethyl acetate 1:1). m.p. 151&#x02013;152 &#x000b0;C; &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3383, 3006, 2834, 1700, 1648, 1618, 1601, 1585, 1502, 1322, 1219, 1198, 1052; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 2.80 (s, 3H), 3.83 (s, 3H), 5.98 (s, 1H), 6.95&#x02013;6.98 (m, 2H), 7.05&#x02013;7.07 (m, 2H), 7.54 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.26 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 25.2, 55.7, 112.3, 115.3 (2C), 121.9 (2C), 126.9, 128.0, 134.4, 145.9, 146.5, 157.9, 161.4, 164.7, 178.3, 183.9; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 296.2 (M+H)<sup>+</sup>, 100%; HRMS (ESI+): Exact mass calculated for C<sub>17</sub>H<sub>14</sub>NO<sub>4</sub> 296.09173. Found 296.09201.</p></sec><sec id="sec3dot2dot4-pharmaceuticals-18-00268"><title>3.2.4. 7-(3-Methoxyphenoxy)-2-methylquinoline-5,8-dione (<bold>5</bold>)</title><p>Potassium carbonate (0.83 g, 6.00 mmol) and 3-methoxyphenol (0.25 g, 2.01 mmol) were added to dimethylformamide (10 mL) and stirred at room temperature for 10 min. 7-bromo-2-methylquinoline-5,8-dione <bold>3</bold> (0.507 g, 2.01 mmol) was then charged, resulting in a dark brown suspension. The reaction mixture was then stirred for a further 2 h and poured over ice water (100 mL), forming a brown precipitate. The crude product was extracted with ethyl acetate (3 &#x000d7; 50 mL). The combined organic layers were washed with saturated sodium sulfite (3 &#x000d7; 50 mL) and brine (2 &#x000d7; 50 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a crude dark orange solid. Flash column chromatography was performed on this crude material (1:0 Hexane:Ethyl acetate&#x02014;1:1 Hexane:Ethyl acetate), yielding the pure product as an orange solid: <bold>5</bold> (0.351 g, 60%) (Rf: 0.4, Hexane-Ethyl acetate 1:1). m.p. 153&#x02013;155 &#x000b0;C; &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3068, 3007, 2845, 1698, 1652, 1608, 1579, 1491, 1474, 1456, 1342, 1319, 1268,1219, 1172, 1136; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 2.81 (s, 3H), 3.83 (s, 3H), 6.05 (s, 1H), 6.69&#x02013;6.75 (m, 2H), 6.87 (dd, <italic toggle="yes">J</italic> = 8.4, 2.0 Hz, 1H), 7.36 (t, <italic toggle="yes">J</italic> = 8.2 Hz, 1H), 7.55 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.28 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 25.2, 55.5, 107.1, 112.4, 112.6, 113.0, 126.9, 128.0, 130.8, 134.5, 146.5, 153.5, 160.7, 161.3, 164.8, 178.2, 183.9; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 296.2 (M+H)<sup>+</sup>, 100%; HRMS (ESI+): Exact mass calculated for C<sub>17</sub>H<sub>14</sub>NO<sub>4</sub> 296.0923. Found 296.0920.</p></sec><sec id="sec3dot2dot5-pharmaceuticals-18-00268"><title>3.2.5. 7-(4-Fluorophenoxy)-2-methylquinoline-5,8-dione (<bold>6</bold>)</title><p>Potassium carbonate (0.661 g, 4.78 mmol) and 4-fluorophenol (0.178 g, 1.59 mmol) were added to dimethylformamide (8 mL) and stirred at room temperature for 10 min. 7-bromo-2-methylquinoline-5,8-dione <bold>3</bold> (0.403 g, 1.59 mmol) was then charged, resulting in a dark brown suspension. The reaction mixture was then stirred for a further 8 h and poured over ice water (100 mL), forming a light brown precipitate. The crude product was extracted with ethyl acetate (3 &#x000d7; 50 mL). The combined organic layers were washed with saturated sodium sulfite (3 &#x000d7; 50 mL) and brine (2 &#x000d7; 50 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a crude dark yellow solid. Flash column chromatography was performed on this crude material (1:0 Hexane:Ethyl acetate&#x02014;4:6 Hexane:Ethyl acetate), yielding the pure product as a bright yellow solid: <bold>6</bold> (0.313 g, 70%) (Rf: 0.3, Hexane-Ethyl acetate 1:1). m.p. 205&#x02013;206 &#x000b0;C (degrad.); &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3367, 3299, 3070, 3041, 2994, 1693, 1659, 1594, 1585, 1501, 1338, 1314, 1237, 1215, 1190, 1139, 1051, 845, 836; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 2.80 (s, 3H), 5.97 (s, 1H), 7.13&#x02013;7.17 (m, 4H), 7.55 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.27 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 25.2, 112.5, 117.2 (d, <italic toggle="yes">J</italic> = 23.7 Hz, 2C), 122.6 (d, <italic toggle="yes">J</italic> = 8.5 Hz, 2C), 126.8, 128.1, 134.5, 146.4, 148.3 (d, <italic toggle="yes">J</italic> = 3.2 Hz), 160.6 (d, <italic toggle="yes">J</italic> = 248 Hz), 160.8, 164.9, 178.1, 183.7; &#x003b4;F (282 MHz, CDCl<sub>3</sub>): &#x02212;114.9 [1F, tt, J 5.0, 5.0 Hz, C(4&#x02032;)F]; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 284.2 (M+H)<sup>+</sup>, 100%; HRMS (ESI+): Exact mass calculated for C<sub>16</sub>H<sub>11</sub>FNO<sub>3</sub> 284.07175. Found 287.07156.</p></sec><sec id="sec3dot2dot6-pharmaceuticals-18-00268"><title>3.2.6. 2-Methyl-7-(4-(cyano)phenoxy)quinoline-5,8-dione (<bold>7</bold>)</title><p>Potassium carbonate (0.889 g, 6.40 mmol) and 4-cyanophenol (0.240 g, 2.01 mmol) were added to dimethylformamide (10 mL) and stirred at room temperature for 10 min. 7-bromo-2-methylquinoline-5,8-dione <bold>3</bold> (0.507 g, 2.00 mmol) was then charged, resulting in a dark brown/red suspension. The reaction mixture was then stirred for a further 3 h and poured over ice water (150 mL). The crude product was extracted with ethyl acetate (3 &#x000d7; 50 mL). The combined organic layers were washed with saturated sodium sulfite (3 &#x000d7; 50 mL) and brine (2 &#x000d7; 50 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a crude brown solid. Flash column chromatography was performed on this crude material (1:0 Hexane:Ethyl acetate&#x02014;4:6 Hexane:Ethyl acetate), yielding the pure product as a bright yellow solid: <bold>7</bold> (0.381 g, 65%) (Rf: 0.3, Hexane-Ethyl acetate 1:1). m.p. 212&#x02013;213 &#x000b0;C (degrad.); &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3056, 2923, 2230, 1694, 1660, 1619, 1596, 1584, 1502, 1317, 1222, 1049; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 2.80 (s, 3H), 6.09 (s, 1H), 7.27&#x02013;7.31 (m, 2H), 7.57 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 7.78&#x02013;7.81 (m, 2H), 8.29 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 25.2, 110.6, 114.3, 117.7, 121.9 (2C), 126.8, 128.3, 134.5, 134.6 (2C), 146.3, 156.2, 159.3, 165.2, 177.6, 183.4; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 291.2 (M+H)<sup>+</sup>, 100%; HRMS (ESI+): Exact mass calculated for C<sub>17</sub>H<sub>11</sub>N<sub>2</sub>O<sub>3</sub> 291.07642. Found 291.07660.</p></sec><sec id="sec3dot2dot7-pharmaceuticals-18-00268"><title>3.2.7. 7-(3,4-Dichlorophenoxy)-2-methylquinoline-5,8-dione (<bold>8</bold>)</title><p>Potassium carbonate (1.64 g, 11.9 mmol) and 3,4-dichlorophenol (0.65 g, 3.99 mmol) were added to dimethylformamide (20 mL) and stirred at room temperature for 10 min. 7-Bromo-2-methylquinoline-5,8-dione <bold>3</bold> (1.00 g, 3.98 mmol) was then charged, resulting in a dark brown suspension. The reaction mixture was then stirred for a further 20 h and poured over ice water (100 mL), forming a brown precipitate. The crude product was extracted with ethyl acetate (3 &#x000d7; 50 mL). The combined organic layers were washed with saturated sodium sulfite (3 &#x000d7; 50 mL) and brine (2 &#x000d7; 50 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a crude dark orange solid. Flash column chromatography was performed on this crude material (1:0 Hexane:Ethyl acetate&#x02014;1:1 Hexane:Ethyl acetate), yielding the pure product as a yellow solid: <bold>8</bold> (0.256 g, 19%) (Rf: 0.5, Hexane-Ethyl acetate 1:1). m.p. 199&#x02013;201 &#x000b0;C; &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3364, 3301, 3069, 3051, 1692, 1616, 1582, 1466, 1392, 1257, 1054; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 2.80 (s, 3H), 6.04 (s, 1H), 7.04 (dd, <italic toggle="yes">J</italic> = 8.7, 2.8 Hz, 1H), 7.30 (d, <italic toggle="yes">J</italic> = 2.7 Hz, 1H), 7.56 (dd, <italic toggle="yes">J</italic> = 8.8, 8.0 Hz, 2H), 8.28 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 25.2, 113.2, 120.6, 123.3, 126.8, 128.2, 131.0, 131.8, 134.2, 134.6, 146.3, 151.3, 160.0, 165.1, 177.7, 183.5; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 334.0 (M+H)<sup>+</sup>, 45%; HRMS (ESI+): Exact mass calculated for C<sub>16</sub>H<sub>10</sub><sup>35</sup>Cl<sub>2</sub>NO<sub>3</sub> 334.0038. Found 334.0026.</p></sec><sec id="sec3dot2dot8-pharmaceuticals-18-00268"><title>3.2.8. 7-(3,4-Difluorophenoxy)-2-methylquinoline-5,8-dione (<bold>9</bold>)</title><p>Potassium carbonate (1.64 g, 11.9 mmol) and 3,4-difluorophenol (0.52 g, 3.97 mmol) were added to dimethylformamide (20 mL) and stirred at room temperature for 10 min. 7-Bromo-2-methylquinoline-5,8-dione <bold>3</bold> (1.00 g, 3.97 mmol) was then charged, resulting in a dark brown suspension. The reaction mixture was then stirred for a further 20 h and poured over ice water (100 mL), forming a brown precipitate. The crude product was extracted with ethyl acetate (3 &#x000d7; 50 mL). The combined organic layers were washed with saturated sodium sulfite (3 &#x000d7; 50 mL) and brine (2 &#x000d7; 50 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a crude dark orange solid. Flash column chromatography was performed on this crude material (1:0 Hexane:Ethyl acetate&#x02014;1:1 Hexane:Ethyl acetate), yielding the pure product as a yellow solid: <bold>9</bold> (0.481 g, 40%) (Rf: 0.3, Hexane-Ethyl acetate 1:1). m.p. 206&#x02013;208 &#x000b0;C; &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3362, 3300, 3067, 3041, 1690, 1658, 1618, 1510, 1437, 1377, 1318, 1251, 1204, 1052; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 2.80 (s, 3H), 6.01 (s, 1H), 6.91&#x02013;6.97 (m, 1H), 7.01&#x02013;7.08 (m, 1H), 7.24&#x02013;7.33 (m, 1H), 7.56 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.28 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 25.2, 111.2 (d, <italic toggle="yes">J</italic> = 19.4 Hz), 112.8, 117.3 (dd, <italic toggle="yes">J</italic> = 8.3, 3.6 Hz), 118.5 (dd, <italic toggle="yes">J</italic> = 19.4, 1.0 Hz), 126.8, 128.2, 134.5, 146.3, 148.1 [dd, <italic toggle="yes">J</italic> = 8.3, 3.6 Hz], 148.8 (dd, <italic toggle="yes">J</italic> = 251, 13.6 Hz), 150.7 (dd, <italic toggle="yes">J</italic> = 251, 13.6 Hz), 160.2, 165.1, 177.8, 183.5; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 302.2 (M+H)<sup>+</sup>, 100%; HRMS (ESI+): Exact mass calculated for C<sub>16</sub>H<sub>10</sub>F<sub>2</sub>NO<sub>3</sub> 302.0620. Found 302.0629.</p></sec><sec id="sec3dot2dot9-pharmaceuticals-18-00268"><title>3.2.9. 7-(3-Chloro-4-fluorophenoxy)-2-methylquinoline-5,8-dione (<bold>10</bold>)</title><p>Potassium carbonate (0.83 g, 6.00 mmol) and 3-chloro-4-fluorophenol (0.29 g, 2.01 mmol) were added to dimethylformamide (10 mL) and stirred at room temperature for 10 min. 7-Bromo-2-methylquinoline-5,8-dione <bold>3</bold> (0.50 g, 2.01 mmol) was then charged, resulting in a dark brown suspension. The reaction mixture was then stirred for a further 20 h and poured over ice water (100 mL), forming a brown precipitate. The crude product was extracted with ethyl acetate (3 &#x000d7; 50 mL). The combined organic layers were washed with saturated sodium sulfite (3 &#x000d7; 50 mL) and brine (2 &#x000d7; 50 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a crude dark orange solid. Flash column chromatography was performed on this crude material (1:0 Hexane:Ethyl acetate&#x02014;1:1 Hexane:Ethyl acetate), yielding the pure product as a yellow solid: <bold>10</bold> (0.046 g, 7%) (Rf: 0.3, Hexane-Ethyl acetate 1:1). m.p. 200&#x02013;202 &#x000b0;C; &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3365, 3300, 3065, 3033, 1690, 1657, 1615, 1493, 1437, 1376, 1256, 1217, 1198, 1053; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 2.80 (s, 3H), 6.00 (s, 1H), 7.04&#x02013;7.09 (m, 1H), 7.23&#x02013;7.29 (m, 2H), 7.56 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.28 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 25.2, 112.9, 118.0 (d, <italic toggle="yes">J</italic> = 23.1 Hz), 120.9 (d, <italic toggle="yes">J</italic> = 7.3 Hz), 122.7 (d, <italic toggle="yes">J</italic> = 19.6 Hz), 123.6, 126.8, 128.2, 134.5, 146.3, 148.4 (d, <italic toggle="yes">J</italic> = 3.4 Hz), 158.1, 160.3, 165.1, 177.8, 183.5; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 318.2 (M+H)<sup>+</sup>, 100%, 320.2 (M+H)<sup>+</sup>, 40%; HRMS (ESI+): Exact mass calculated for C<sub>16</sub>H<sub>10</sub><sup>35</sup>ClFNO<sub>3</sub> 318.0323. Found 318.0333.</p></sec><sec id="sec3dot2dot10-pharmaceuticals-18-00268"><title>3.2.10. 7-(4-(2-Hydroxyethyl)phenoxy)-2-methylquinoline-5,8-dione (<bold>11</bold>)</title><p>Potassium carbonate (1.64 g, 11.8 mmol) and 2-(4-hydroxyphenol)-ethanol (0.55 g, 3.97 mmol) were added to dimethylformamide (20 mL) and stirred at room temperature for 10 min. 7-Bromo-2-methylquinoline-5,8-dione <bold>3</bold> (1.0 g, 3.97 mmol) was then charged, resulting in a dark brown suspension. The reaction mixture was then stirred for a further 20 h and poured over ice water (100 mL), forming a brown precipitate. The crude product was extracted with ethyl acetate (3 &#x000d7; 50 mL). The combined organic layers were washed with saturated sodium sulfite (3 &#x000d7; 50 mL) and brine (2 &#x000d7; 50 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a crude dark orange solid. Flash column chromatography was performed on this crude material (1:0 Hexane:Ethyl acetate&#x02014;7:3 Hexane:Ethyl acetate), yielding the pure product as a yellow solid: <bold>11</bold> (0.288 g, 23%) (Rf: 0.2, Hexane-Ethyl acetate 1:1). m.p. 195&#x02013;197 &#x000b0;C; &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3404, 3100, 3060, 3020, 2960, 1693, 1610, 1517, 1462, 1442, 1376, 1248, 1089, 1071; &#x003b4;H (300 MHz, <italic toggle="yes"><sub>d6</sub></italic>-DMSO): 2.68 (s, 3H), 3.04 (t, <italic toggle="yes">J</italic> = 7.0 Hz, 2H), 4.26 (t, <italic toggle="yes">J</italic> = 7.0 Hz, 2H), 6.42 (s, 1H), 6.74 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 2H), 7.18 (d, <italic toggle="yes">J</italic> = 8.4 Hz, 2H), 7.72 (d, <italic toggle="yes">J</italic> = 6.0 Hz, 1H), 8.24 (d, <italic toggle="yes">J</italic> = 8.1 Hz, 1H), 9.27 (s, 1H); &#x003b4;C (75 MHz, <italic toggle="yes"><sub>d6</sub></italic>-DMSO): 24.9, 33.7, 70.6, 109.9, 115.4, 115.6, 127.0, 128.0, 128.2, 130.1, 130.4, 134.4, 146.7, 156.4, 160.3, 163.9, 178.3, 184.4; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 310.3 (M+H)<sup>+</sup>, 80%; HRMS (ESI+): Exact mass calculated for C<sub>18</sub>H<sub>16</sub>NO<sub>4</sub> 310.10738. Found 310.10697.</p></sec><sec id="sec3dot2dot11-pharmaceuticals-18-00268"><title>3.2.11. 7-(4-Bromophenoxy)-2-methylquinoline-5,8-dione (<bold>12</bold>)</title><p>Potassium carbonate (0.885 g, 6.40 mmol) and 4-bromophenol (0.361 g, 2.09 mmol) were added to dimethylformamide (10 mL) and stirred at room temperature for 10 min. 7-bromo-2-methylquinoline-5,8-dione <bold>3</bold> (0.504 g, 1.99 mmol) was then charged, resulting in a dark brown suspension. The reaction mixture was then stirred for a further 6 h and poured over ice water (150 mL), forming a light brown precipitate. The crude product was extracted with ethyl acetate (3 &#x000d7; 50 mL). The combined organic layers were washed with saturated sodium sulfite (3 &#x000d7; 50 mL) and brine (2 &#x000d7; 50 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a crude dark yellow solid. Flash column chromatography was performed on this crude material (1:0 Hexane:Ethyl acetate&#x02014;1:1 Hexane:Ethyl acetate), yielding the pure product as a yellow solid: <bold>6</bold> (0.4565 g, 66%) (Rf: 0.4, Hexane-Ethyl acetate 1:1). m.p. 174&#x02013;176 &#x000b0;C; &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3357, 3068, 2959, 2856, 1693, 1656, 1637, 1576, 1482, 1340, 1315, 1219, 1199, 1138, 1068, 1050, 1011, 843; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 2.80 (s, 3H), 5.99 (s, 1H), 7.04&#x02013;7.07 (m, 2H), 7.55 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 7.58&#x02013;7.61 (m, 2H), 8.27 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 25.2, 112.7, 120.0, 122.9 (2C), 126.8, 128.1, 133.6 (2C), 134.5, 146.4, 151.6, 160.4, 165.0, 178.0, 183.6; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 344.1 (M+H)<sup>+</sup>, 80%, 346.1 (M+H)<sup>+</sup>, 100%; HRMS (ESI+): Exact mass calculated for C<sub>16</sub>H<sub>11</sub><sup>79</sup>BrNO<sub>3</sub> 343.99168. Found 343.99213.</p></sec><sec id="sec3dot2dot12-pharmaceuticals-18-00268"><title>3.2.12. 7-(4-Methoxyphenoxy)-5,8-dioxo-5,8-dihydroquinoline-2-carbaldehyde (<bold>13</bold>)</title><p>7-(4-Methoxyphenoxy)-2-methyl-6,7-dihydroquinoline-5,8-dione <bold>4</bold> (0.147 g, 0.50 mmol) was dissolved in 1,4-dioxane (11 mL) at room temperature with stirring, resulting in an orange solution. Selenium dioxide (0.103 g, 0.93 mmol) was then added, and the reaction mixture was heated to 90 &#x000b0;C for 18 h, resulting in a dark orange solution with black precipitate. The reaction mixture was filtered through a Celite pad and washed through with dichloromethane (30 mL). The filtrate was concentrated under reduced pressure, yielding a dark orange oil. This crude material was re-dissolved in dichloromethane (30 mL) and washed with brine (2 &#x000d7; 15 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a crude orange solid. The crude solid was subjected to flash column chromatography (1:0 Hexane:Ethyl acetate&#x02014;7:3 Hexane:Ethyl acetate), resulting in the product as an orange solid: <bold>13</bold> (0.0776 g, 50%) (Rf: 0.5, Hexane-Ethyl acetate 1:1). m.p. 230&#x02013;233 &#x000b0;C (decomp.); &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3402, 3061, 2963, 1703, 1704, 1650, 1601, 1505, 1317, 1225, 1196, 1128, 1040; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 3.85 (s, 3H), 6.13 (s, 1H), 6.98 (d, <italic toggle="yes">J</italic> = 9.1 Hz, 2H), 7.08 (d, <italic toggle="yes">J</italic> = 9.1 Hz, 2H), 8.31 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.59 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 10.34 (s, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 55.7, 112.9, 115.5 (2C), 121.8 (2C), 125.1, 131.2, 136.2, 145.6, 147.1, 155.5, 158.2, 162.0, 177.3, 182.7, 191.9; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 310.2 (M+H)<sup>+</sup>, 40%; HRMS (ESI+): Exact mass calculated for C<sub>17</sub>H<sub>12</sub>NO<sub>5</sub> 310.07100. Found 310.07081.</p></sec><sec id="sec3dot2dot13-pharmaceuticals-18-00268"><title>3.2.13. 7-(3-Methoxyphenoxy)-5,8-dioxo-5,8-dihydroquinoline-2-carbaldehyde (<bold>14</bold>)</title><p>7-(3-Methoxyphenoxy)-2-methylquinoline-5,8-dione <bold>5</bold> (0.303 g, 1.03 mmol) was dissolved in 1,4-dioxane (25 mL) with stirring at room temperature, resulting in a yellow solution. Selenium dioxide (0.227 g, 2.05 mmol) was then added. The reaction mixture was heated to 90 &#x000b0;C for 18 h, resulting in a yellow solution with a black precipitate. The solution was filtered into a Celite pad and washed with dichloromethane. Then, the solution was concentrated under reduced pressure, resulting in a red/orange powder. The powder was dissolved in dichloromethane (30 mL), and the solution was washed with brine (2 &#x000d7; 15 mL). The product was dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a red/orange powder. Flash column chromatography was performed on this crude material (1:0 Hexane:Ethyl acetate&#x02014;1:1 Hexane:Ethyl acetate), yielding the pure product as a yellow/orange solid: <bold>4</bold> (0.085 g, 27%) (Rf: 0.6, Hexane-Ethyl acetate 1:1). m.p. 186&#x02013;188 &#x000b0;C; &#x003bd;<sub>max</sub>/cm<sub>-1</sub> (KBr): 3376, 3065, 2962, 2922, 2839, 1711, 1696, 1657, 1610, 1586, 1487, 1319, 1221, 1168, 1126, 1046; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 3.84 (s, 3H), 6.18 (s, 1H), 6.70&#x02013;6.77 (m, 2H), 6.89 (dd, <italic toggle="yes">J</italic> = 8.4, 2.4 Hz, 1H), 7.39 (t, <italic toggle="yes">J</italic> = 8.2 Hz, 1H), 8.31 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.60 (dd, <italic toggle="yes">J</italic> = 8.0, 0.7 Hz, 1H), 10.34 (s, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 55.6, 107.0, 112.7, 112.8, 113.2, 125.1, 131.0, 131.2, 136.2, 147.1, 153.3, 155.5, 161.40, 161.43, 177.2, 182.7, 191.8; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 332.1 (M+Na)<sup>+</sup>, 84%, 350.1 (M+K)<sup>+</sup>, 100%; HRMS (ESI+): Exact mass calculated for C<sub>17</sub>H<sub>11</sub>NO<sub>5</sub><sup>23</sup>Na 332.0535. Found 332.0523.</p></sec><sec id="sec3dot2dot14-pharmaceuticals-18-00268"><title>3.2.14. 7-(4-Fluorophenoxy)-5,8-dioxo-5,8-dihydroquinoline-2-carbaldehyde (<bold>15</bold>)</title><p>7-(4-Fluorophenoxy)-2-methylquinoline-5,8-dione <bold>8</bold> (0.1507 g, 0.53 mmol) was dissolved in 1,4-dioxane (12 mL) at room temperature with stirring, resulting in a yellow solution. Selenium dioxide (0.121 g, 1.09 mmol) was then added, and the reaction mixture was heated to 90 &#x000b0;C for 18 h, resulting in an orange solution with black precipitate. The reaction mixture was filtered through a Celite pad and washed through with dichloromethane (30 mL). The filtrate was concentrated under reduced pressure, yielding a crude yellow solid. This crude material was re-dissolved in dichloromethane (30 mL) and washed with brine (2 &#x000d7; 15 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a crude yellow solid. The crude solid was subjected to flash column chromatography (1:0 Hexane:Ethyl acetate&#x02014;1:1 Hexane:Ethyl acetate), resulting in the product as a pale yellow solid: <bold>15</bold> (0.0853 g, 54%) (Rf: 0.5, Hexane-Ethyl acetate 1:1). m.p. 219&#x02013;220 &#x000b0;C (degrad.); &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3078, 2872, 1718, 1706, 1654, 1608, 1593, 1503, 1351, 1382, 1217, 1037; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 6.11 (s, 1H), 7.16&#x02013;7.20 (m, 4H), 8.32 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.60 (dd, <italic toggle="yes">J</italic> = 8.0, 0.7 Hz, 1H), 10.34 (s, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 113.1, 117.4 (d, <italic toggle="yes">J</italic> = 24 Hz, 2C), 122.5 (d, <italic toggle="yes">J</italic> = 9.0 Hz, 2C), 125.2, 131.2, 136.2, 147.1, 148.1 (d, <italic toggle="yes">J</italic> = 2.8 Hz), 155.5, 160.9 (d, <italic toggle="yes">J</italic> = 247 Hz), 161.5, 177.0, 182.5, 191.8; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 298.1 (M+H)<sup>+</sup>, 25%, 320.1 (M+Na)<sup>+</sup>, 85%, 338.1 (M+K)<sup>+</sup>, 60%; HRMS (ESI+): Exact mass calculated for C<sub>16</sub>H<sub>9</sub>NO<sub>4</sub>F 298.05101. Found 298.05143.</p></sec><sec id="sec3dot2dot15-pharmaceuticals-18-00268"><title>3.2.15. 7-(3,4-Dichlorophenoxy)-5,8-dioxo-5,8-dihydroquinoline-2-carbaldehyde (<bold>17</bold>)</title><p>7-(3,4-Dichlorophenoxy)-2-methylquinoline-5,8-dione <bold>10</bold> (0.122 g, 0.366 mmol) was dissolved in 1,4-dioxane (10 mL) with stirring at room temperature, resulting in a yellow solution. Selenium dioxide (0.081 g, 0.732 mmol) was then added. The reaction mixture was heated to 90 &#x000b0;C for 18 h, resulting in a yellow solution with a black precipitate. The solution was filtered into a Celite pad and washed with dichloromethane. Then, the solution was concentrated under reduced pressure, resulting in a red/orange powder. The powder was dissolved in dichloromethane (30 mL), and the solution was washed with brine (2 &#x000d7; 15 mL). The product was dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a red/orange powder. Flash column chromatography was performed on this crude material (1:0 Hexane:Ethyl acetate&#x02014;7:3 Hexane:Ethyl acetate), yielding the pure product as a yellow/orange solid: <bold>17</bold> (0.056 g, 44%) (Rf: 0.7, Hexane-Ethyl acetate 1:1). m.p. 201&#x02013;203 &#x000b0;C; &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3391, 3052, 2924, 2854, 1722, 1704, 1652, 1614, 1585, 1467, 1253, 1042; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 6.18 (s, 1H), 7.07 (dd, <italic toggle="yes">J</italic> = 8.8, 2.7 Hz, 1H), 7.33 (d, <italic toggle="yes">J</italic> = 2.6 Hz, 1H), 7.59 (d, <italic toggle="yes">J</italic> = 8.8 Hz, 1H), 8.33 (d, <italic toggle="yes">J</italic> = 8.2 Hz, 1H), 8.61 (dd, <italic toggle="yes">J</italic> = 8.0, 0.8 Hz, 1H), 10.33 (d, <italic toggle="yes">J</italic> = 0.7 Hz, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 113.7, 120.5, 123.3, 125.3, 131.1, 131.4, 132.0, 134.4, 136.3, 147.0, 151.0, 155.6, 160.6, 176.7, 182.3, 191.7; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 365.9 (M+H)<sup>+</sup>, 60%, 367.9 (M+H)<sup>+</sup>, 40%, 369.9 (M+H)<sup>+</sup>, 30%; HRMS (ESI+): Exact mass calculated for C<sub>16</sub>H<sub>10</sub><sup>35</sup>Cl<sub>2</sub>NO<sub>5</sub> 365.9936. Found 365.9926.</p></sec><sec id="sec3dot2dot16-pharmaceuticals-18-00268"><title>3.2.16. 7-(3,4-Difluorophenoxy)-5,8-dioxo-5,8-dihydroquinoline-2-carbaldehyde (<bold>18</bold>)</title><p>7-(3,4-Difluorophenoxy)-2-methylquinoline-5,8-dione <bold>9</bold> (0.168 g, 5.56 mmol) was dissolved in 1,4-dioxane (15 mL) with stirring at room temperature, resulting in a yellow solution. Selenium dioxide (0.124 g, 1.12 mmol) was then added. The reaction mixture was heated to 90 &#x000b0;C for 18 h, resulting in a yellow solution with a black precipitate. The solution was filtered into a Celite pad and washed with dichloromethane. Then, the solution was concentrated under reduced pressure, resulting in a red/orange powder. The powder was dissolved in dichloromethane (30 mL), and the solution was washed with brine (2 &#x000d7; 15 mL). The product was dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a yellow powder. Flash column chromatography was performed on this crude material (1:0 Hexane:Ethyl acetate&#x02014;7:3 Hexane:Ethyl acetate), yielding the pure product as a yellow/orange solid: <bold>18</bold> (0.070 g, 40%) (Rf: 0.7, Hexane-Ethyl acetate 1:1). m.p. 194&#x02013;196 &#x000b0;C; &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3396, 3076, 3044, 2924, 2843, 1709, 1653, 1614, 1509, 1433, 1322, 1224, 1039; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 6.16 (s, 1H), 6.93&#x02013;6.99 (m, 1H), 7.04&#x02013;7.10 (m, 1H), 7.27&#x02013;7.36 (m, 1H), 8.33 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.61 (dd, <italic toggle="yes">J</italic> = 8.0, 0.8 Hz, 1H), 10.33 (d, <italic toggle="yes">J</italic> = 0.9 Hz, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 111.2 (d, <italic toggle="yes">J</italic> = 19.7 Hz), 113.5, 117.1 (d, <italic toggle="yes">J</italic> = 6.0 Hz), 118.7 (d, <italic toggle="yes">J</italic> = 19.7 Hz), 125.2, 131.1, 136.3, 147.0, 147.8 (dd, <italic toggle="yes">J</italic> = 6.0, 4.1 Hz), 149.1 (dd, <italic toggle="yes">J</italic> = 250, 13.5 Hz), 150.8 (dd, <italic toggle="yes">J</italic> = 250, 13.5 Hz), 155.6, 160.9, 176.7, 182.4, 191.7; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI-): 316.2 (M-H)<sup>&#x02212;</sup>, 47%; HRMS (ESI-): Exact mass calculated for C<sub>16</sub>H<sub>8</sub>F<sub>2</sub>NO<sub>4</sub> 316.0421. Found 316.0410.</p></sec><sec id="sec3dot2dot17-pharmaceuticals-18-00268"><title>3.2.17. 7-(4-Bromophenoxy)-5,8-dioxo-5,8-dihydroquinoline-2-carbaldehyde (<bold>19</bold>)</title><p>7-(4-bromophenoxy)-2-methylquinoline-5,8-dione <bold>12</bold> (0.413 g, 1.20 mmol) was dissolved in 1,4-dioxane (30 mL) at room temperature with stirring, resulting in an orange solution. Selenium dioxide (0.271 g, 2.44 mmol) was then added, and the reaction mixture was heated to 90 &#x000b0;C for 18 h, resulting in an orange solution with black precipitate. The reaction mixture was filtered through a Celite pad and washed through with dichloromethane (50 mL). The filtrate was concentrated under reduced pressure, yielding a crude yellow solid. This crude material was re-dissolved in dichloromethane (50 mL) and washed with brine (2 &#x000d7; 30 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure, yielding a crude yellow solid. The crude solid was subjected to flash column chromatography (1:0 Hexane:Ethyl acetate&#x02014;7:3 Hexane:Ethyl acetate), resulting in the product as a fluffy yellow solid: <bold>19</bold> (0.391 g, 91%) (Rf: 0.5, Hexane-Ethyl acetate 1:1). m.p. 230&#x02013;232 &#x000b0;C (degrad.); &#x003bd;<sub>max</sub>/cm<sup>&#x02212;1</sup> (KBr): 3063, 2868, 1718, 1704, 1647, 1610, 1578, 1563, 1482, 1354, 1320, 1235, 1200, 1039; &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 6.13 (s, 1H), 7.07 (d, <italic toggle="yes">J</italic> = 9.0 Hz, 2H), 7.63 (d, <italic toggle="yes">J</italic> = 9.0 Hz, 2H), 8.32 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.60 (dd, <italic toggle="yes">J</italic> = 8.0, 0.8 Hz, 1H), 10.33 (d, <italic toggle="yes">J</italic> = 0.8 Hz, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 113.3, 120.4, 122.8 (2C), 125.2, 131.2, 133.8 (2C), 136.2, 147.0, 151.4, 155.6, 161.0, 176.9, 182.4, 191.7; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 358.0 (M+H)<sup>+</sup>, 20%, 260.0 (M+H)<sup>+</sup>, 20%. HRMS (ESI+): Exact mass calculated for C<sub>16</sub>H<sub>9</sub><sup>79</sup>BrNO<sub>4</sub> 357.97095. Found 357.97081.</p></sec><sec id="sec3dot2dot18-pharmaceuticals-18-00268"><title>3.2.18. (<italic toggle="yes">R</italic>)-2-((2-(Hydroxymethyl)pyrrolidin-1-yl)methyl)-7-(4-methoxyphenoxy)quinoline-5,8-dione (<bold>20</bold>)</title><p>Sodium triacetoxyborohydride (0.187 g, 0.88 mmol) was added to a solution of 7-(4-Methoxyphenoxy)-5,8-dioxo-5,8-dihydroquinoline-2-carbaldehyde <bold>13</bold> (0.171 g, 0.55 mmol) in dichloroethane (14 mL). D-Prolinol (0.059 g, 0.58 mmol) was weighed, and dichloroethane (2 mL) was added to the solution. This solution was added dropwise to the reaction mixture over 2 min, resulting in a cloudy brown suspension. The solution was stirred at room temperature for 12 h, resulting in an orange suspension. Dichloromethane (30 mL) was added, and the organic layer was washed with saturated sodium bicarbonate (3 &#x000d7; 30 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure to yield a crude brown oil. The crude project was subjected to flash chromatography (0:1 Methanol: Dichloromethane&#x02014;1:99 Methanol: Dichloromethane), resulting in an orange oil: <bold>20</bold> (0.0797 g, 37%); &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 1.78&#x02013;1.86 (m, 1H), 1.97&#x02013;2.02 (m, 1H), 2.51 (q, <italic toggle="yes">J</italic> = 8.9 Hz, 1H), 2.92&#x02013;2.96 (m, 1H), 3.08&#x02013;3.12 (m, 1H), 3.18 (bs, 1H), 3.52 (dd, <italic toggle="yes">J</italic> = 11.2, 3.5 Hz, 1H), 3.64 (dd, <italic toggle="yes">J</italic> = 11.2, 3.5 Hz, 1H), 3.84 (s, 3H), 3.98 (d, <italic toggle="yes">J</italic> = 15.4 Hz, 1H), 4.31 (d, <italic toggle="yes">J</italic> = 15.4 Hz 1H), 6.00 (s, 1H), 6.95&#x02013;6.99 (m, 2H), 7.03&#x02013;7.07 (m, 2H), 7.84 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.36 (d, <italic toggle="yes">J</italic> = 8.0 Hz 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 23.7, 27.4, 55.1, 55.7, 60.4, 62.7, 65.5, 112.4, 115.4 (2C), 121.9 (2C), 127.0, 127.8, 134.9, 145.8, 146.3, 158.0, 161.4, 165.9, 178.1, 183.7; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 395.2 (M+H)<sup>+</sup>, 100%; HRMS (ESI+): Exact mass calculated for C<sub>22</sub>H<sub>22</sub>N<sub>2</sub>O<sub>5</sub> 395.16015. Found 395.15927.</p></sec><sec id="sec3dot2dot19-pharmaceuticals-18-00268"><title>3.2.19. (<italic toggle="yes">R</italic>)-7-(4-Fluorophenoxy)-2-((2-(hydroxymethyl)pyrrolidin-1-yl)methyl)quinoline-5,8-dione (<bold>21</bold>)</title><p>Sodium triacetoxyborohydride (0.0759 g, 0.36 mmol) was added to a solution of 7-(4 Fluorophenoxy)-5,8-dioxo-5,8-dihydroquinoline-2-carbaldehyde <bold>15</bold> (0.0651 g, 0.22 mmol) in dichloroethane (4 mL). D-Prolinol (0.0216 g, 0.21 mmol) was weighed, and dichloroethane (1 mL) was added to the solution. This solution was added dropwise to the reaction mixture over 2 min, resulting in a cloudy brown suspension. The solution was stirred at room temperature for 12 h, resulting in an orange suspension. Dichloromethane (15 mL) was added, and the organic layer was washed with saturated sodium bicarbonate (3 &#x000d7; 10 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure to yield a crude brown oil. The crude project was subjected to flash chromatography (0:1 Methanol:Dichloromethane&#x02014;3:97 Methanol:Dichloromethane), resulting in a light brown oil: <bold>21</bold> (0.031 g, 38%) (Rf: 0.6, Hexane-Ethyl acetate 1:1). &#x003b4;H (300 MHz, CDCl<sub>3</sub>): 1.76&#x02013;2.01 (m, 2H), 2.50 (q, <italic toggle="yes">J</italic> = 8.9 Hz, 1H), 2.83 (bs, 1H), 2.90&#x02013;2.93 (m, 1H), 3.07&#x02013;3.09 (m, 1H), 3.50 (dd, <italic toggle="yes">J</italic> = 11.2, 3.5 Hz, 1H), 3.63 (dd, <italic toggle="yes">J</italic> = 11.2, 3.5 Hz, 1H), 3.97 (d, <italic toggle="yes">J</italic> = 15.2 Hz, 1H), 4.28 (d, <italic toggle="yes">J</italic> = 15.2 Hz, 1H), 5.98 (s, 1H), 7.12&#x02013;7.20 (m, 4H), 7.85 (d, <italic toggle="yes">J</italic> = 8.2 Hz, 1H), 8.36 (d, <italic toggle="yes">J</italic> = 8.2 Hz, 1H); &#x003b4;C (75 MHz, CDCl<sub>3</sub>): 23.7, 27.4, 55.1, 60.4, 62.7, 65.5, 112.6, 117.2 (d, <italic toggle="yes">J</italic> = 23.7 Hz, 2C), 122.6 (d, <italic toggle="yes">J</italic> = 6.7 Hz, 2C), 127.1, 127.7, 135.0, 146.2, 148.3 (d, <italic toggle="yes">J</italic> = 2.9 Hz), 160.7 (d, <italic toggle="yes">J</italic> = 247 Hz), 160.9, 166.1, 177.8, 183.6; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (ESI+): 383.2 (M+H)<sup>+</sup>, 95%, 384.2 (M+2H)<sup>+</sup>, 25%; HRMS (ESI+): Exact mass calculated for C<sub>21</sub>H<sub>19</sub>FN<sub>2</sub>O<sub>4</sub> 383.14016. Found 383.13978.</p></sec></sec><sec id="sec3dot3-pharmaceuticals-18-00268"><title>3.3. Sphingosine Kinase Assays</title><p>A fluorometric assay was developed using a sphingosine derivative labelled with a 7-nitrobenz-2-oxa-1,3-diazole moiety (NBD-Sphingosine, Sigma-Aldrich, Arklow, Ireland, #810205P) and recombinant human SphK1 and SphK2 enzymes (Sigma-Aldrich, Arklow, Ireland, #SRP0283, #SRP0287, respectively) [<xref rid="B41-pharmaceuticals-18-00268" ref-type="bibr">41</xref>]. The relevant enzymes and inhibitors were incubated in total reaction volumes of 100 &#x000b5;L with 10 &#x000b5;M NBD-sphingosine, 500 &#x000b5;M 4-deoxypyridoxine and 1 mM Mg-ATP in assay buffer (100 mM Tris/HCl (pH 7.4), 150 mM NaCl, 2 mM Na<sub>3</sub>VO<sub>4</sub> and 10 mM NaF) for 30 min at 37 &#x000b0;C. A reaction mixture containing no test SphK inhibitor served as the positive control, while a reaction mixture containing no Mg-ATP served as the negative control. Post-incubation, 100 &#x000b5;L of potassium phosphate buffer, pH 8.5, was added to each Eppendorf, followed by 500 &#x000b5;L of 2:1 Chloroform/Methanol. After brief mixing with a vortex, phases were separated by centrifugation at 2000 rpm for 5 min. The aqueous phase (100 &#x000b5;L) of each sample was then transferred to wells of a black 96-well flat-bottom plate, and fluorescent intensity was measured at Ex/Em 485/535 nm using a Wallac Victor2 Multilabel plate reader (Perkin Elmer, Dublin, Ireland). Data are expressed as mean SD from a minimum of 2 independent experiments. To calculate the concentrations of fluorescent product generated, a standard curve of NBD-S1P (Sigma-Aldrich, #810207X) was set up in the range of 0.1&#x02013;10 &#x000b5;M. From this, the IC<sub>50</sub> values of several test inhibitors were calculated.</p></sec><sec id="sec3dot4-pharmaceuticals-18-00268"><title>3.4. Cancer Cell Growth Assays (NCI60 Screening)</title><p>One-dose study: Tested compounds were initially solubilised in DMSO, diluted into RPMI 1640 and 5% fetal bovine serum/L-glutamine and added to 96-well plates containing cell lines previously cultured for 24 h. After 48 h of incubation, the media were removed, and the cells were fixed and stained with sulforhodamine B to determine overall percent growth/total protein content. Unbound dye was removed with five washes of 1% acetic acid, and the plates were allowed to air dry. The dye was then resolubilised in Tris buffer, and the colourimetric absorbance was measured (515 nm). Growth inhibition was measured relative to the response generated from proliferating cells cultured under identical conditions for 48 h. Data from one-dose experiments pertain to the percentage growth at 10 &#x003bc;M [<xref rid="B60-pharmaceuticals-18-00268" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceuticals-18-00268" ref-type="bibr">61</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceuticals-18-00268"><title>4. Conclusions</title><p>A series of novel C(7)-aryl-ether quinoline-5,8-diones were synthesised in yields of up to 84%. Structural modifications to the aryl region were performed to probe SphK and anticancer activities. This is the first time quinoline-5,8-diones have been reported to possess both SphK1 and SphK2 inhibitory activity. <italic toggle="yes">Para</italic>-substituted quinoline-5,8-diones <bold>6</bold> and <bold>7</bold> exhibited inhibition of both SphK1 and SphK2 (&#x0003e;50%), which is comparable to the clinically used anticancer agent opaganib, and <bold>4</bold> identified a level of selectivity for SphK1. The introduction of <italic toggle="yes">meta</italic> halogen substituents resulted in lower yields and reduced SphK activity.</p><p>Encouraged by these preliminary findings, a pyrrolidine headgroup was adapted from PF-543 and designed in the quinoline-5,8-dione framework to improve SphK1 inhibition. Two novel pyrrolidine quinoline-5,8-dione analogues were synthesised, <bold>20</bold> and <bold>21,</bold> which were accessed through novel C(2)-activated formyl intermediates. An improvement in SphK1 binding efficacy for <bold>21</bold> (70%) was observed relative to the parent compound <bold>6</bold> (54%). Molecular modelling was undertaken on pyrrolidine quinoline-5,8-dione <bold>21,</bold> revealing low binding energies and no major unfavourable steric hindrance. Compound <bold>21</bold> is revealed to access a polar region previously unknown for SphK inhibitors, which will be further developed in the future. Compound <bold>4</bold> is identified with an IC<sub>50</sub> of 30 and 8 &#x000b5;M, respectively, against Sphk1 and SphK2 (and <bold>20</bold> with values of 42 and 13 &#x000b5;M, respectively). Although minimal anticancer activity was observed in vitro, low micromolar dual SphK1/2 inhibition with the quinoline-5,8-dione framework has been identified for the first time with a plausible binding mode to guide future efforts.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to acknowledge Denis Lynch for NMR and MS services.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceuticals-18-00268"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/ph18020268/s1">https://www.mdpi.com/article/10.3390/ph18020268/s1</uri>. Data S1.1. <sup>1</sup>H and <sup>13</sup>C NMR Supporting Information for compounds <bold>2</bold>&#x02013;<bold>21</bold>; Figure S1. HPLC chromatogram of compound <bold>4</bold>. Figure S2. HPLC chromatograms of compound <bold>20</bold>. Figure S3. NBD-S1P Fluorescence Standard Curve. Figure S4. Assay validation and standards. Figure S5. In silico ADME parameters of <bold>4</bold>. Figure S6. In silico ADME parameters of <bold>20</bold>. Figure S7 NCI One dose data for Compound <bold>4</bold>. Figure S8. NCI One dose data for Compound <bold>5</bold>. Figure S9. NCI One dose data for Compound <bold>6</bold>. Figure S10. NCI One dose data for Compound <bold>7</bold>. Figure S11. NCI One dose data for Compound <bold>12</bold>. Table S1. Peak purity of HPLC chromatogram for compounds <bold>4</bold> and <bold>20</bold>. Table S2. SK inhibition assay validation with control compounds PF-543 and ABC284640. Table S3. SK inhibition assay data for <bold>5</bold>-<bold>7</bold>, <bold>11</bold> and <bold>20</bold>. Table S4. SK inhibition assay data for <bold>8</bold>-<bold>10</bold>, <bold>14</bold>-<bold>15</bold> and <bold>18</bold>-<bold>19</bold>. Table S5. SK inhibition assay data for <bold>4</bold>, <bold>13</bold> and <bold>21</bold>. Table S6. In silico SphK1 Docking Score and Lipophilicity.</p><supplementary-material id="pharmaceuticals-18-00268-s001" position="float" content-type="local-data"><media xlink:href="pharmaceuticals-18-00268-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualisation, project administration, funding acquisition, F.O.M.; methodology/synthesis and modelling, R.D.K.; methodology/screening and bioactivity, K.M.; supervision: F.O.M. and C.W.; writing&#x02014;original draft preparation, F.O.M.; writing&#x02014;review and editing, F.O.M., R.D.K., A.N.W., K.M. and C.W.; visualisation, R.D.K. and F.O.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data are available through <xref rid="app1-pharmaceuticals-18-00268" ref-type="app">Supplementary Materials</xref> or by request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><glossary><title>Abbreviations</title><p>CLK1: CDC Like Kinase 1; DHS, dihydrosphingosine; DMS, dimethyl sphingosine; Met, Mesenchymal Epithelial Transition; MST2, Mammalian Ste-20-like Kinase 2; NQO1, NAD(P)H:quinone oxidoreductase 1; NBD, 7-nitrobenz-2-oxa-1,3-diazole; NCI, National Cancer Institute; PDB, Protein Data Bank; PLANTS, Protein&#x02212;Ligand ANT System; PLP, Piecewise Linear Potential; SphK, Sphingosine Kinase; S1P, sphingosine-1-phosphate.</p></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00268"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pitman</surname><given-names>M.R.</given-names></name>
<name><surname>Costabile</surname><given-names>M.</given-names></name>
<name><surname>Pitson</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Recent advances in the development of sphingosine kinase inhibitors</article-title><source>Cell Signal.</source><year>2016</year><volume>28</volume><fpage>1349</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2016.06.007</pub-id><pub-id pub-id-type="pmid">27297359</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-18-00268"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>W.L.</given-names></name>
<name><surname>Lynch</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Drugging Sphingosine Kinases</article-title><source>ACS Chem. Biol.</source><year>2015</year><volume>10</volume><fpage>225</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1021/cb5008426</pub-id><pub-id pub-id-type="pmid">25384187</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-18-00268"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neubauer</surname><given-names>H.A.</given-names></name>
<name><surname>Pitson</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Roles, regulation and inhibitors of sphingosine kinase 2</article-title><source>FEBS J.</source><year>2013</year><volume>280</volume><fpage>5317</fpage><lpage>5336</lpage><pub-id pub-id-type="doi">10.1111/febs.12314</pub-id><pub-id pub-id-type="pmid">23638983</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-18-00268"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pyne</surname><given-names>N.J.</given-names></name>
<name><surname>Pyne</surname><given-names>S.</given-names></name>
</person-group><article-title>Recent advances in the role of sphingosine 1-phosphate in cancer</article-title><source>FEBS Lett.</source><year>2020</year><volume>594</volume><fpage>3583</fpage><lpage>3601</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.13933</pub-id><pub-id pub-id-type="pmid">32969034</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-18-00268"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pyne</surname><given-names>N.J.</given-names></name>
<name><surname>Pyne</surname><given-names>S.</given-names></name>
</person-group><article-title>Sphingosine 1-phosphate and cancer</article-title><source>Nat. Rev. Cancer</source><year>2010</year><volume>10</volume><fpage>489</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1038/nrc2875</pub-id><pub-id pub-id-type="pmid">20555359</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-18-00268"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wattenberg</surname><given-names>B.W.</given-names></name>
<name><surname>Pitson</surname><given-names>S.M.</given-names></name>
<name><surname>Raben</surname><given-names>D.M.</given-names></name>
</person-group><article-title>The sphingosine and diacylglycerol kinase superfamily of signaling kinases: Localization as a key to signaling function</article-title><source>J. Lipid Res.</source><year>2006</year><volume>47</volume><fpage>1128</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1194/jlr.R600003-JLR200</pub-id><pub-id pub-id-type="pmid">16520486</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-18-00268"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Echten-Deckert</surname><given-names>G.</given-names></name>
<name><surname>Hagen-Euteneuer</surname><given-names>N.</given-names></name>
<name><surname>Karaca</surname><given-names>I.</given-names></name>
<name><surname>Walter</surname><given-names>J.</given-names></name>
</person-group><article-title>Sphingosine-1-Phosphate: Boon and Bane for the Brain</article-title><source>Cell. Physiol. Biochem.</source><year>2014</year><volume>34</volume><fpage>148</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1159/000362991</pub-id><pub-id pub-id-type="pmid">24977488</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00268"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pyne</surname><given-names>N.J.</given-names></name>
<name><surname>Pyne</surname><given-names>S.</given-names></name>
</person-group><article-title>Sphingosine Kinase 1: A Potential Therapeutic Target in Pulmonary Arterial Hypertension?</article-title><source>Trends Mol. Med.</source><year>2017</year><volume>23</volume><fpage>786</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2017.07.001</pub-id><pub-id pub-id-type="pmid">28789830</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00268"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Horga</surname><given-names>A.</given-names></name>
<name><surname>Montalban</surname><given-names>X.</given-names></name>
</person-group><article-title>FTY720 (fingolimod) for relapsing multiple sclerosis</article-title><source>Expert Rev. Neurother.</source><year>2008</year><volume>8</volume><fpage>699</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1586/14737175.8.5.699</pub-id><pub-id pub-id-type="pmid">18457527</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-18-00268"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bonica</surname><given-names>J.</given-names></name>
<name><surname>Mao</surname><given-names>C.</given-names></name>
<name><surname>Obeid</surname><given-names>L.M.</given-names></name>
<name><surname>Hannun</surname><given-names>Y.A.</given-names></name>
</person-group><article-title>Transcriptional Regulation of Sphingosine Kinase 1</article-title><source>Cells</source><year>2020</year><volume>9</volume><elocation-id>2437</elocation-id><pub-id pub-id-type="doi">10.3390/cells9112437</pub-id><pub-id pub-id-type="pmid">33171624</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-18-00268"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Plano</surname><given-names>D.</given-names></name>
<name><surname>Amin</surname><given-names>S.</given-names></name>
<name><surname>Sharma</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Importance of Sphingosine Kinase (SphK) as a Target in Developing Cancer Therapeutics and Recent Developments in the Synthesis of Novel SphK Inhibitors</article-title><source>J. Med. Chem.</source><year>2014</year><volume>57</volume><fpage>5509</fpage><lpage>5524</lpage><pub-id pub-id-type="doi">10.1021/jm4011687</pub-id><pub-id pub-id-type="pmid">24471412</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-18-00268"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Su</surname><given-names>L.</given-names></name>
<name><surname>Tian</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Han</surname><given-names>N.</given-names></name>
<name><surname>Feng</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Lentivirus-mediated siRNA knockdown of SPHK1 inhibits proliferation and tumorigenesis of neuroblastoma</article-title><source>OncoTargets Ther.</source><year>2018</year><volume>11</volume><fpage>7187</fpage><lpage>7196</lpage><pub-id pub-id-type="doi">10.2147/OTT.S180962</pub-id><pub-id pub-id-type="pmid">30425511</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-18-00268"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Orr Gandy</surname><given-names>K.A.</given-names></name>
<name><surname>Obeid</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: Review of sphingosine kinase inhibitors</article-title><source>Biochim. Biophys. Acta. Spec. Sect. Mol. Cell Biol. Lipids</source><year>2013</year><volume>1831</volume><fpage>157</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2012.07.002</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-18-00268"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Houck</surname><given-names>J.D.</given-names></name>
<name><surname>Dawson</surname><given-names>T.K.</given-names></name>
<name><surname>Kennedy</surname><given-names>A.J.</given-names></name>
<name><surname>Kharel</surname><given-names>Y.</given-names></name>
<name><surname>Naimon</surname><given-names>N.D.</given-names></name>
<name><surname>Field</surname><given-names>S.D.</given-names></name>
<name><surname>Lynch</surname><given-names>K.R.</given-names></name>
<name><surname>Macdonald</surname><given-names>T.L.</given-names></name>
</person-group><article-title>Structural Requirements and Docking Analysis of Amidine-Based Sphingosine Kinase 1 Inhibitors Containing Oxadiazoles</article-title><source>ACS Med. Chem. Lett.</source><year>2016</year><volume>7</volume><fpage>487</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.6b00002</pub-id><pub-id pub-id-type="pmid">27190598</pub-id>
</element-citation></ref><ref id="B15-pharmaceuticals-18-00268"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cuvillier</surname><given-names>O.</given-names></name>
</person-group><article-title>Downregulating sphingosine kinase-1 for cancer therapy</article-title><source>Expert Opin. Ther. Targets</source><year>2008</year><volume>12</volume><fpage>1009</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1517/14728222.12.8.1009</pub-id><pub-id pub-id-type="pmid">18620522</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-18-00268"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>M.</given-names></name>
<name><surname>Ji</surname><given-names>C.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>Ni</surname><given-names>W.</given-names></name>
<name><surname>Tong</surname><given-names>X.</given-names></name>
<name><surname>Wei</surname><given-names>J.-F.</given-names></name>
</person-group><article-title>Sphingosine kinase inhibitors: A patent review</article-title><source>Int. J. Mol. Med.</source><year>2018</year><volume>41</volume><fpage>2450</fpage><lpage>2460</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2018.3505</pub-id><pub-id pub-id-type="pmid">29484372</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-18-00268"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yi</surname><given-names>X.</given-names></name>
<name><surname>Tang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>He</surname><given-names>H.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Xiang</surname><given-names>C.</given-names></name>
<name><surname>Cao</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Therapeutic potential of the sphingosine kinase 1 inhibitor, PF-543</article-title><source>Biomed. Pharm.</source><year>2023</year><volume>163</volume><elocation-id>114401</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2023.114401</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-18-00268"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ju</surname><given-names>T.</given-names></name>
<name><surname>Gao</surname><given-names>D.</given-names></name>
<name><surname>Fang</surname><given-names>Z.-Y.</given-names></name>
</person-group><article-title>Targeting colorectal cancer cells by a novel sphingosine kinase 1 inhibitor PF-543</article-title><source>Biochem. Biophys. Res. Comm.</source><year>2016</year><volume>470</volume><fpage>728</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2016.01.053</pub-id><pub-id pub-id-type="pmid">26775841</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-18-00268"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamada</surname><given-names>M.</given-names></name>
<name><surname>Kameyama</surname><given-names>H.</given-names></name>
<name><surname>Iwai</surname><given-names>S.</given-names></name>
<name><surname>Yura</surname><given-names>Y.</given-names></name>
</person-group><article-title>Induction of autophagy by sphingosine kinase 1 inhibitor PF-543 in head and neck squamous cell carcinoma cells</article-title><source>Cell Death Discov.</source><year>2017</year><volume>3</volume><fpage>17047</fpage><pub-id pub-id-type="doi">10.1038/cddiscovery.2017.47</pub-id><pub-id pub-id-type="pmid">29109864</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-18-00268"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Gao</surname><given-names>F.</given-names></name>
<name><surname>Chen</surname><given-names>K.</given-names></name>
<name><surname>Tian</surname><given-names>M.L.</given-names></name>
<name><surname>Zhao</surname><given-names>D.L.</given-names></name>
</person-group><article-title>Sphingosine kinase 1 as an anticancer therapeutic target</article-title><source>Drug Des. Devel. Ther.</source><year>2015</year><volume>9</volume><fpage>3239</fpage><lpage>3245</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S83288</pub-id></element-citation></ref><ref id="B21-pharmaceuticals-18-00268"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Britten</surname><given-names>C.D.</given-names></name>
<name><surname>Garrett-Mayer</surname><given-names>E.</given-names></name>
<name><surname>Chin</surname><given-names>S.H.</given-names></name>
<name><surname>Shirai</surname><given-names>K.</given-names></name>
<name><surname>Ogretmen</surname><given-names>B.</given-names></name>
<name><surname>Bentz</surname><given-names>T.A.</given-names></name>
<name><surname>Brisendine</surname><given-names>A.</given-names></name>
<name><surname>Anderton</surname><given-names>K.</given-names></name>
<name><surname>Cusack</surname><given-names>S.L.</given-names></name>
<name><surname>Maines</surname><given-names>L.W.</given-names></name>
<etal/>
</person-group><article-title>A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors</article-title><source>Clin. Cancer Res.</source><year>2017</year><volume>23</volume><fpage>4642</fpage><lpage>4652</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-2363</pub-id><pub-id pub-id-type="pmid">28420720</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00268"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>French</surname><given-names>K.J.</given-names></name>
<name><surname>Zhuang</surname><given-names>Y.</given-names></name>
<name><surname>Maines</surname><given-names>L.W.</given-names></name>
<name><surname>Gao</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Beljanski</surname><given-names>V.</given-names></name>
<name><surname>Upson</surname><given-names>J.J.</given-names></name>
<name><surname>Green</surname><given-names>C.L.</given-names></name>
<name><surname>Keller</surname><given-names>S.N.</given-names></name>
<name><surname>Smith</surname><given-names>C.D.</given-names></name>
</person-group><article-title>Pharmacology and Antitumor Activity of ABC294640, a Selective Inhibitor of Sphingosine Kinase-2</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2010</year><volume>333</volume><fpage>129</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1124/jpet.109.163444</pub-id><pub-id pub-id-type="pmid">20061445</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-18-00268"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>C.S.</given-names></name>
<name><surname>Voelkel-Johnson</surname><given-names>C.</given-names></name>
<name><surname>Smith</surname><given-names>C.D.</given-names></name>
</person-group><article-title>Targeting Sphingosine Kinases for the Treatment of Cancer</article-title><source>Adv. Cancer Res.</source><year>2018</year><volume>140</volume><fpage>295</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">30060814</pub-id>
</element-citation></ref><ref id="B24-pharmaceuticals-18-00268"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maines</surname><given-names>L.W.</given-names></name>
<name><surname>Keller</surname><given-names>S.N.</given-names></name>
<name><surname>Smith</surname><given-names>C.D.</given-names></name>
</person-group><article-title>Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>16901</elocation-id><pub-id pub-id-type="doi">10.3390/ijms242316901</pub-id><pub-id pub-id-type="pmid">38069222</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-18-00268"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lynch</surname><given-names>K.R.</given-names></name>
<name><surname>Thorpe</surname><given-names>S.B.</given-names></name>
<name><surname>Santos</surname><given-names>W.L.</given-names></name>
</person-group><article-title>Sphingosine kinase inhibitors: A review of patent literature (2006&#x02013;2015)</article-title><source>Expert Opin. Ther. Pat.</source><year>2016</year><volume>26</volume><fpage>1409</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1080/13543776.2016.1226282</pub-id><pub-id pub-id-type="pmid">27539678</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00268"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dickson</surname><given-names>M.A.</given-names></name>
<name><surname>Carvajal</surname><given-names>R.D.</given-names></name>
<name><surname>Merrill</surname><given-names>A.H.</given-names></name>
<name><surname>Gonen</surname><given-names>M.</given-names></name>
<name><surname>Cane</surname><given-names>L.M.</given-names></name>
<name><surname>Schwartz</surname><given-names>G.K.</given-names></name>
</person-group><article-title>A Phase I Clinical Trial of Safingol in Combination with Cisplatin in Advanced Solid Tumors</article-title><source>Clin. Cancer Res.</source><year>2011</year><volume>17</volume><fpage>2484</fpage><lpage>2492</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2323</pub-id><pub-id pub-id-type="pmid">21257722</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-18-00268"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noack</surname><given-names>J.</given-names></name>
<name><surname>Choi</surname><given-names>J.</given-names></name>
<name><surname>Richter</surname><given-names>K.</given-names></name>
<name><surname>Kopp-Schneider</surname><given-names>A.</given-names></name>
<name><surname>R&#x000e9;gnier-Vigouroux</surname><given-names>A.</given-names></name>
</person-group><article-title>A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy</article-title><source>Cell Death Dis.</source><year>2014</year><volume>5</volume><fpage>e1425</fpage><pub-id pub-id-type="doi">10.1038/cddis.2014.384</pub-id><pub-id pub-id-type="pmid">25255218</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-18-00268"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>P.</given-names></name>
<name><surname>Peterson</surname><given-names>Y.K.</given-names></name>
<name><surname>Smith</surname><given-names>R.A.</given-names></name>
<name><surname>Smith</surname><given-names>C.D.</given-names></name>
</person-group><article-title>Characterization of isoenzyme-selective inhibitors of human sphingosine kinases</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>44543</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0044543</pub-id></element-citation></ref><ref id="B29-pharmaceuticals-18-00268"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kono</surname><given-names>K.</given-names></name>
<name><surname>Tanaka</surname><given-names>M.</given-names></name>
<name><surname>Ogita</surname><given-names>T.</given-names></name>
<name><surname>Hosoya</surname><given-names>T.</given-names></name>
<name><surname>Kohama</surname><given-names>T.</given-names></name>
</person-group><article-title>F-12509A, a New Sphingosine Kinase Inhibitor, Produced by a Discomycete</article-title><source>J. Antibiot.</source><year>2000</year><volume>53</volume><fpage>459</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.53.459</pub-id></element-citation></ref><ref id="B30-pharmaceuticals-18-00268"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kadela-Tomanek</surname><given-names>M.</given-names></name>
<name><surname>B&#x00119;benek</surname><given-names>E.</given-names></name>
<name><surname>Chrobak</surname><given-names>E.</given-names></name>
<name><surname>Boryczka</surname><given-names>S.</given-names></name>
</person-group><article-title>5,8-Quinolinedione Scaffold as a Promising Moiety of Bioactive Agents</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>4115</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24224115</pub-id><pub-id pub-id-type="pmid">31739496</pub-id>
</element-citation></ref><ref id="B31-pharmaceuticals-18-00268"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kadela-Tomanek</surname><given-names>M.</given-names></name>
<name><surname>Jastrzebska</surname><given-names>M.</given-names></name>
<name><surname>Chrobak</surname><given-names>E.</given-names></name>
<name><surname>Bebenek</surname><given-names>E.</given-names></name>
<name><surname>Latocha</surname><given-names>M.</given-names></name>
</person-group><article-title>Hybrids of 1,4-Quinone with Quinoline Derivatives: Synthesis, Biological Activity, and Molecular Docking with DT-Diaphorase (NQO1)</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>6206</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27196206</pub-id><pub-id pub-id-type="pmid">36234741</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-18-00268"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hussain</surname><given-names>H.</given-names></name>
<name><surname>Specht</surname><given-names>S.</given-names></name>
<name><surname>Sarite</surname><given-names>S.R.</given-names></name>
<name><surname>Hoerauf</surname><given-names>A.</given-names></name>
<name><surname>Krohn</surname><given-names>K.</given-names></name>
</person-group><article-title>New quinoline-5,8-dione and hydroxynaphthoquinone derivatives inhibit a chloroquine resistant Plasmodium falciparum strain</article-title><source>Eur. J. Med. Chem.</source><year>2012</year><volume>54</volume><fpage>936</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2012.06.046</pub-id><pub-id pub-id-type="pmid">22781704</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-18-00268"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lam</surname><given-names>K.-H.</given-names></name>
<name><surname>Gambari</surname><given-names>R.</given-names></name>
<name><surname>Lee</surname><given-names>K.K.-H.</given-names></name>
<name><surname>Chen</surname><given-names>Y.-X.</given-names></name>
<name><surname>Kok</surname><given-names>S.H.-L.</given-names></name>
<name><surname>Wong</surname><given-names>R.S.-M.</given-names></name>
<name><surname>Lau</surname><given-names>F.-Y.</given-names></name>
<name><surname>Cheng</surname><given-names>C.-H.</given-names></name>
<name><surname>Wong</surname><given-names>W.-Y.</given-names></name>
<name><surname>Bian</surname><given-names>Z.-X.</given-names></name>
<etal/>
</person-group><article-title>Preparation of 8-hydroxyquinoline derivatives as potential antibiotics against Staphylococcus aureus</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2014</year><volume>24</volume><fpage>367</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2013.10.072</pub-id><pub-id pub-id-type="pmid">24269165</pub-id>
</element-citation></ref><ref id="B34-pharmaceuticals-18-00268"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Egu</surname><given-names>S.A.</given-names></name>
<name><surname>Okoro</surname><given-names>U.C.</given-names></name>
<name><surname>Onoabedje</surname><given-names>E.A.</given-names></name>
</person-group><article-title>New Aryl Derivatives of Quinolinedione and Related Heterocyclic Compounds</article-title><source>J. Het. Chem.</source><year>2017</year><volume>54</volume><fpage>1572</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1002/jhet.2745</pub-id></element-citation></ref><ref id="B35-pharmaceuticals-18-00268"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choi</surname><given-names>H.Y.</given-names></name>
<name><surname>Chi</surname><given-names>D.Y.</given-names></name>
</person-group><article-title>Simple preparation of 7-alkylamino-2-methylquinoline-5,8-diones: Regiochemistry in nucleophilic substitution reactions of the 6- or 7-bromo-2-methylquinoline-5,8-dione with amines</article-title><source>Tetrahedron</source><year>2004</year><volume>60</volume><fpage>4945</fpage><lpage>4951</lpage><pub-id pub-id-type="doi">10.1016/j.tet.2004.04.041</pub-id></element-citation></ref><ref id="B36-pharmaceuticals-18-00268"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>V&#x000e1;zquez</surname><given-names>K.</given-names></name>
<name><surname>Espinosa-Bustos</surname><given-names>C.</given-names></name>
<name><surname>Soto-Delgado</surname><given-names>J.</given-names></name>
<name><surname>Tapia</surname><given-names>R.A.</given-names></name>
<name><surname>Varela</surname><given-names>J.</given-names></name>
<name><surname>Birriel</surname><given-names>E.</given-names></name>
<name><surname>Segura</surname><given-names>R.</given-names></name>
<name><surname>Pizarro</surname><given-names>J.</given-names></name>
<name><surname>Cerecetto</surname><given-names>H.</given-names></name>
<name><surname>Gonz&#x000e1;lez</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>New aryloxy-quinone derivatives as potential anti-Chagasic agents: Synthesis, trypanosomicidal activity, electrochemical properties, pharmacophore elucidation and 3D-QSAR analysis</article-title><source>RSC Adv.</source><year>2015</year><volume>5</volume><fpage>65153</fpage><lpage>65166</lpage><pub-id pub-id-type="doi">10.1039/C5RA10122K</pub-id></element-citation></ref><ref id="B37-pharmaceuticals-18-00268"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Verniest</surname><given-names>G.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Kimpe</surname><given-names>N.D.</given-names></name>
<name><surname>Padwa</surname><given-names>A.</given-names></name>
</person-group><article-title>Heteroaryl Cross-Coupling as an Entry toward the Synthesis of Lavendamycin Analogues: A Model Study</article-title><source>J. Org. Chem.</source><year>2010</year><volume>75</volume><fpage>424</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1021/jo902287t</pub-id><pub-id pub-id-type="pmid">20017470</pub-id>
</element-citation></ref><ref id="B38-pharmaceuticals-18-00268"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Priimagi</surname><given-names>A.</given-names></name>
<name><surname>Cavallo</surname><given-names>G.</given-names></name>
<name><surname>Metrangolo</surname><given-names>P.</given-names></name>
<name><surname>Resnati</surname><given-names>G.</given-names></name>
</person-group><article-title>The Halogen Bond in the Design of Functional Supramolecular Materials: Recent Advances</article-title><source>Acc. Chem. Res.</source><year>2013</year><volume>46</volume><fpage>2686</fpage><lpage>2695</lpage><pub-id pub-id-type="doi">10.1021/ar400103r</pub-id><pub-id pub-id-type="pmid">23805801</pub-id>
</element-citation></ref><ref id="B39-pharmaceuticals-18-00268"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gentry</surname><given-names>C.L.</given-names></name>
<name><surname>Egleton</surname><given-names>R.D.</given-names></name>
<name><surname>Gillespie</surname><given-names>T.</given-names></name>
<name><surname>Abbruscato</surname><given-names>T.J.</given-names></name>
<name><surname>Bechowski</surname><given-names>H.B.</given-names></name>
<name><surname>Hruby</surname><given-names>V.J.</given-names></name>
<name><surname>Davis</surname><given-names>T.P.</given-names></name>
</person-group><article-title>The effect of halogenation on blood&#x02013;brain barrier permeability of a novel peptide drug</article-title><source>Peptides</source><year>1999</year><volume>20</volume><fpage>1229</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1016/S0196-9781(99)00127-8</pub-id><pub-id pub-id-type="pmid">10573295</pub-id>
</element-citation></ref><ref id="B40-pharmaceuticals-18-00268"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ho</surname><given-names>P.S.</given-names></name>
</person-group><article-title>Halogen bonding in medicinal chemistry: From observation to prediction</article-title><source>Future Med. Chem.</source><year>2017</year><volume>9</volume><fpage>637</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.4155/fmc-2017-0052</pub-id><pub-id pub-id-type="pmid">28485645</pub-id>
</element-citation></ref><ref id="B41-pharmaceuticals-18-00268"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lima</surname><given-names>S.</given-names></name>
<name><surname>Milstien</surname><given-names>S.</given-names></name>
<name><surname>Spiegel</surname><given-names>S.</given-names></name>
</person-group><article-title>A real-time high-throughput fluorescence assay for sphingosine kinases</article-title><source>J. Lipid Res.</source><year>2014</year><volume>55</volume><fpage>1525</fpage><lpage>1530</lpage><pub-id pub-id-type="doi">10.1194/jlr.D048132</pub-id><pub-id pub-id-type="pmid">24792926</pub-id>
</element-citation></ref><ref id="B42-pharmaceuticals-18-00268"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.B.</given-names></name>
<name><surname>Lee</surname><given-names>T.</given-names></name>
<name><surname>Moon</surname><given-names>H.S.</given-names></name>
<name><surname>Ki</surname><given-names>S.H.</given-names></name>
<name><surname>Oh</surname><given-names>Y.S.</given-names></name>
<name><surname>Lee</surname><given-names>J.-Y.</given-names></name>
<name><surname>Kim</surname><given-names>S.-B.</given-names></name>
<name><surname>Park</surname><given-names>J.-E.</given-names></name>
<name><surname>Kwon</surname><given-names>Y.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Verification of the Necessity of the Tolyl Group of PF-543 for Sphingosine Kinase 1 Inhibitory Activity</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>2484</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25112484</pub-id><pub-id pub-id-type="pmid">32471162</pub-id>
</element-citation></ref><ref id="B43-pharmaceuticals-18-00268"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vettorazzi</surname><given-names>M.</given-names></name>
<name><surname>Angelina</surname><given-names>E.</given-names></name>
<name><surname>Lima</surname><given-names>S.</given-names></name>
<name><surname>Gonec</surname><given-names>T.</given-names></name>
<name><surname>Otevrel</surname><given-names>J.</given-names></name>
<name><surname>Marvanova</surname><given-names>P.</given-names></name>
<name><surname>Padrtova</surname><given-names>T.</given-names></name>
<name><surname>Mokry</surname><given-names>P.</given-names></name>
<name><surname>Bobal</surname><given-names>P.</given-names></name>
<name><surname>Acosta</surname><given-names>L.M.</given-names></name>
<etal/>
</person-group><article-title>An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors</article-title><source>Eur. J. Med. Chem.</source><year>2017</year><volume>139</volume><fpage>461</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.08.017</pub-id><pub-id pub-id-type="pmid">28822281</pub-id>
</element-citation></ref><ref id="B44-pharmaceuticals-18-00268"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Corvino</surname><given-names>A.</given-names></name>
<name><surname>Rosa</surname><given-names>R.</given-names></name>
<name><surname>Incisivo</surname><given-names>G.M.</given-names></name>
<name><surname>Fiorino</surname><given-names>F.</given-names></name>
<name><surname>Frecentese</surname><given-names>F.</given-names></name>
<name><surname>Magli</surname><given-names>E.</given-names></name>
<name><surname>Perissutti</surname><given-names>E.</given-names></name>
<name><surname>Saccone</surname><given-names>E.</given-names></name>
<name><surname>Santagada</surname><given-names>V.</given-names></name>
<name><surname>Cirino</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Development of 1,2,3-Triazole-Based Sphingosine Kinase Inhibitors and Their Evaluation as Antiproliferative Agent</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>2332</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18112332</pub-id><pub-id pub-id-type="pmid">29113071</pub-id>
</element-citation></ref><ref id="B45-pharmaceuticals-18-00268"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shrestha</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>S.W.</given-names></name>
<name><surname>Kim</surname><given-names>S.-B.</given-names></name>
<name><surname>Oh</surname><given-names>Y.S.</given-names></name>
<name><surname>Ki</surname><given-names>S.H.</given-names></name>
<name><surname>Lee</surname><given-names>T.</given-names></name>
<name><surname>Kim</surname><given-names>S.-B.</given-names></name>
<name><surname>Park</surname><given-names>T.</given-names></name>
<name><surname>Baek</surname><given-names>D.J.</given-names></name>
<name><surname>Park</surname><given-names>E.-Y.</given-names></name>
</person-group><article-title>Determining the Anticancer Activity of Sphingosine Kinase Inhibitors Containing Heteroatoms in Their Tail Structure</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>157</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14010157</pub-id><pub-id pub-id-type="pmid">35057052</pub-id>
</element-citation></ref><ref id="B46-pharmaceuticals-18-00268"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Sibley</surname><given-names>C.D.</given-names></name>
<name><surname>Kharel</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>T.</given-names></name>
<name><surname>Brown</surname><given-names>A.M.</given-names></name>
<name><surname>Wonilowicz</surname><given-names>L.G.</given-names></name>
<name><surname>Bevan</surname><given-names>D.R.</given-names></name>
<name><surname>Lynch</surname><given-names>K.R.</given-names></name>
<name><surname>Santos</surname><given-names>W.L.</given-names></name>
</person-group><article-title>Lipophilic tail modifications of 2-(hydroxymethyl)pyrrolidine scaffold reveal dual sphingosine kinase 1 and 2 inhibitors</article-title><source>Bioorg. Med. Chem.</source><year>2021</year><volume>30</volume><elocation-id>115941</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmc.2020.115941</pub-id><pub-id pub-id-type="pmid">33385956</pub-id>
</element-citation></ref><ref id="B47-pharmaceuticals-18-00268"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.B.</given-names></name>
<name><surname>Oh</surname><given-names>Y.S.</given-names></name>
<name><surname>Kim</surname><given-names>K.J.</given-names></name>
<name><surname>Cho</surname><given-names>S.W.</given-names></name>
<name><surname>Park</surname><given-names>S.K.</given-names></name>
<name><surname>Baek</surname><given-names>D.J.</given-names></name>
<name><surname>Park</surname><given-names>E.-Y.</given-names></name>
</person-group><article-title>Synthesis of PP2A-Activating PF-543 Derivatives and Investigation of Their Inhibitory Effects on Pancreatic Cancer Cells</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>3346</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27103346</pub-id><pub-id pub-id-type="pmid">35630821</pub-id>
</element-citation></ref><ref id="B48-pharmaceuticals-18-00268"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Knapp</surname><given-names>S.</given-names></name>
<name><surname>Pyne</surname><given-names>N.J.</given-names></name>
<name><surname>Pyne</surname><given-names>S.</given-names></name>
<name><surname>Elkins</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Crystal Structure of Sphingosine Kinase 1 with PF-543</article-title><source>ACS Med. Chem. Lett.</source><year>2014</year><volume>5</volume><fpage>1329</fpage><lpage>1333</lpage><pub-id pub-id-type="doi">10.1021/ml5004074</pub-id><pub-id pub-id-type="pmid">25516793</pub-id>
</element-citation></ref><ref id="B49-pharmaceuticals-18-00268"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adams</surname><given-names>D.R.</given-names></name>
<name><surname>Pyne</surname><given-names>S.</given-names></name>
<name><surname>Pyne</surname><given-names>N.J.</given-names></name>
</person-group><article-title>Sphingosine Kinases: Emerging Structure-Function Insights</article-title><source>Trends Biochem. Sci.</source><year>2016</year><volume>41</volume><fpage>395</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2016.02.007</pub-id><pub-id pub-id-type="pmid">27021309</pub-id>
</element-citation></ref><ref id="B50-pharmaceuticals-18-00268"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adams</surname><given-names>D.R.</given-names></name>
<name><surname>Tawati</surname><given-names>S.</given-names></name>
<name><surname>Berretta</surname><given-names>G.</given-names></name>
<name><surname>Rivas</surname><given-names>P.L.</given-names></name>
<name><surname>Baiget</surname><given-names>J.</given-names></name>
<name><surname>Jiang</surname><given-names>Z.</given-names></name>
<name><surname>Alsfouk</surname><given-names>A.</given-names></name>
<name><surname>Mackay</surname><given-names>S.P.</given-names></name>
<name><surname>Pyne</surname><given-names>N.J.</given-names></name>
<name><surname>Pyne</surname><given-names>S.</given-names></name>
</person-group><article-title>Topographical Mapping of Isoform-Selectivity Determinants for J-Channel-Binding Inhibitors of Sphingosine Kinases 1 and 2</article-title><source>J. Med. Chem.</source><year>2019</year><volume>62</volume><fpage>3658</fpage><lpage>3676</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00162</pub-id><pub-id pub-id-type="pmid">30889352</pub-id>
</element-citation></ref><ref id="B51-pharmaceuticals-18-00268"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seradj</surname><given-names>H.</given-names></name>
<name><surname>Cai</surname><given-names>W.</given-names></name>
<name><surname>Erasga</surname><given-names>N.O.</given-names></name>
<name><surname>Chenault</surname><given-names>D.V.</given-names></name>
<name><surname>Knuckles</surname><given-names>K.A.</given-names></name>
<name><surname>Ragains</surname><given-names>J.R.</given-names></name>
<name><surname>Behforouz</surname><given-names>M.</given-names></name>
</person-group><article-title>Total Synthesis of Novel 6-Substituted Lavendamycin Antitumor Agents</article-title><source>Org. Lett.</source><year>2004</year><volume>6</volume><fpage>473</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1021/ol035381a</pub-id><pub-id pub-id-type="pmid">14961601</pub-id>
</element-citation></ref><ref id="B52-pharmaceuticals-18-00268"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hassani</surname><given-names>M.</given-names></name>
<name><surname>Cai</surname><given-names>W.</given-names></name>
<name><surname>Holley</surname><given-names>D.C.</given-names></name>
<name><surname>Lineswala</surname><given-names>J.P.</given-names></name>
<name><surname>Maharjan</surname><given-names>B.R.</given-names></name>
<name><surname>Ebrahimian</surname><given-names>G.R.</given-names></name>
<name><surname>Seradj</surname><given-names>H.</given-names></name>
<name><surname>Stocksdale</surname><given-names>M.G.</given-names></name>
<name><surname>Mohammadi</surname><given-names>F.</given-names></name>
<name><surname>Marvin</surname><given-names>C.C.</given-names></name>
<etal/>
</person-group><article-title>Novel Lavendamycin Analogues as Antitumor Agents:&#x02009; Synthesis, in Vitro Cytotoxicity, Structure&#x02212;Metabolism, and Computational Molecular Modeling Studies with NAD(P)H:Quinone Oxidoreductase 1</article-title><source>J. Med. Chem.</source><year>2005</year><volume>48</volume><fpage>7733</fpage><lpage>7749</lpage><pub-id pub-id-type="doi">10.1021/jm050758z</pub-id><pub-id pub-id-type="pmid">16302813</pub-id>
</element-citation></ref><ref id="B53-pharmaceuticals-18-00268"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>W.</given-names></name>
<name><surname>Hassani</surname><given-names>M.</given-names></name>
<name><surname>Karki</surname><given-names>R.</given-names></name>
<name><surname>Walter</surname><given-names>E.D.</given-names></name>
<name><surname>Koelsch</surname><given-names>K.H.</given-names></name>
<name><surname>Seradj</surname><given-names>H.</given-names></name>
<name><surname>Lineswala</surname><given-names>J.P.</given-names></name>
<name><surname>Mirzaei</surname><given-names>H.</given-names></name>
<name><surname>York</surname><given-names>J.S.</given-names></name>
<name><surname>Olang</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Synthesis, metabolism and in vitro cytotoxicity studies on novel lavendamycin antitumor agents</article-title><source>Bioorg. Med. Chem.</source><year>2010</year><volume>18</volume><fpage>1899</fpage><lpage>1909</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2010.01.037</pub-id><pub-id pub-id-type="pmid">20149966</pub-id>
</element-citation></ref><ref id="B54-pharmaceuticals-18-00268"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schnute</surname><given-names>M.E.</given-names></name>
<name><surname>Mcreynolds</surname><given-names>M.D.</given-names></name>
<name><surname>Carroll</surname><given-names>J.</given-names></name>
<name><surname>Chrencik</surname><given-names>J.</given-names></name>
<name><surname>Highkin</surname><given-names>M.K.</given-names></name>
<name><surname>Iyanar</surname><given-names>K.</given-names></name>
<name><surname>Jerome</surname><given-names>G.</given-names></name>
<name><surname>Rains</surname><given-names>J.W.</given-names></name>
<name><surname>Saabye</surname><given-names>M.</given-names></name>
<name><surname>Scholten</surname><given-names>J.A.</given-names></name>
<etal/>
</person-group><article-title>Discovery of a Potent and Selective Sphingosine Kinase 1 Inhibitor through the Molecular Combination of Chemotype-Distinct Screening Hits</article-title><source>J. Med. Chem.</source><year>2017</year><volume>60</volume><fpage>2562</fpage><lpage>2572</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00070</pub-id><pub-id pub-id-type="pmid">28231433</pub-id>
</element-citation></ref><ref id="B55-pharmaceuticals-18-00268"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Korb</surname><given-names>O.</given-names></name>
<name><surname>St&#x000fc;tzle</surname><given-names>T.</given-names></name>
<name><surname>Exner</surname><given-names>T.E.</given-names></name>
</person-group><article-title>Empirical scoring functions for advanced protein-ligand docking with PLANTS</article-title><source>J. Chem. Inf. Model.</source><year>2009</year><volume>49</volume><fpage>84</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1021/ci800298z</pub-id><pub-id pub-id-type="pmid">19125657</pub-id>
</element-citation></ref><ref id="B56-pharmaceuticals-18-00268"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Daina</surname><given-names>A.</given-names></name>
<name><surname>Michielin</surname><given-names>O.</given-names></name>
<name><surname>Zoete</surname><given-names>V.</given-names></name>
</person-group><article-title>SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>42717</fpage><lpage>42730</lpage><pub-id pub-id-type="doi">10.1038/srep42717</pub-id><pub-id pub-id-type="pmid">28256516</pub-id>
</element-citation></ref><ref id="B57-pharmaceuticals-18-00268"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alkafaas</surname><given-names>S.S.</given-names></name>
<name><surname>Elsalahaty</surname><given-names>M.I.</given-names></name>
<name><surname>Ismail</surname><given-names>D.F.</given-names></name>
<name><surname>Radwan</surname><given-names>M.A.</given-names></name>
<name><surname>Elkafas</surname><given-names>S.S.</given-names></name>
<name><surname>Loutfy</surname><given-names>S.A.</given-names></name>
<name><surname>Elshazli</surname><given-names>R.M.</given-names></name>
<name><surname>Baazaoui</surname><given-names>N.</given-names></name>
<name><surname>Ahmed</surname><given-names>A.E.</given-names></name>
<name><surname>Hafez</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: A promising therapeutic target</article-title><source>Cancer Cell Int.</source><year>2024</year><volume>24</volume><fpage>89</fpage><pub-id pub-id-type="doi">10.1186/s12935-024-03221-8</pub-id><pub-id pub-id-type="pmid">38419070</pub-id>
</element-citation></ref><ref id="B58-pharmaceuticals-18-00268"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fer</surname><given-names>N.D.</given-names></name>
<name><surname>Shoemaker</surname><given-names>R.H.</given-names></name>
<name><surname>Monks</surname><given-names>A.</given-names></name>
</person-group><article-title>Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2010</year><volume>29</volume><fpage>91</fpage><pub-id pub-id-type="doi">10.1186/1756-9966-29-91</pub-id><pub-id pub-id-type="pmid">20618971</pub-id>
</element-citation></ref><ref id="B59-pharmaceuticals-18-00268"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Petrow</surname><given-names>V.</given-names></name>
<name><surname>Sturgeon</surname><given-names>B.</given-names></name>
</person-group><article-title>Some Quinoline-5,8-diones</article-title><source>J. Chem. Soc.</source><year>1954</year><fpage>570</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1039/jr9540000570</pub-id></element-citation></ref><ref id="B60-pharmaceuticals-18-00268"><label>60.</label><element-citation publication-type="gov"><article-title>National Cancer Institute Developmental Therapeutics Program. NCI-60 Human Tumour Cell Lines Screen</article-title><comment>Available online: <ext-link xlink:href="https://dtp.cancer.gov/discovery_development/nci-60/default.htm" ext-link-type="uri">https://dtp.cancer.gov/discovery_development/nci-60/default.htm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-11">(accessed on 11 November 2024)</date-in-citation></element-citation></ref><ref id="B61-pharmaceuticals-18-00268"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shoemaker</surname><given-names>R.H.</given-names></name>
</person-group><article-title>The NCI60 human tumour cell line anticancer drug screen</article-title><source>Nat. Rev. Cancer</source><year>2006</year><volume>6</volume><fpage>813</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1038/nrc1951</pub-id><pub-id pub-id-type="pmid">16990858</pub-id>
</element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Schemes and Tables</title><fig position="float" id="pharmaceuticals-18-00268-f001"><label>Figure 1</label><caption><p>Sphingosine and representative examples of sphingosine kinase inhibitors. Representative fragments are coloured for the polar headgroup (pink), the linker (blue) and lipophilic tail (red) moieties.</p></caption><graphic xlink:href="pharmaceuticals-18-00268-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00268-f002"><label>Figure 2</label><caption><p>Quinone-based SphK inhibitors CB5468139 and F12509A.</p></caption><graphic xlink:href="pharmaceuticals-18-00268-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00268-f003"><label>Figure 3</label><caption><p>Naphthoquinone CB5468139 and our quinoline-5,8-dione SphK inhibitor framework.</p></caption><graphic xlink:href="pharmaceuticals-18-00268-g003" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00268-sch001"><object-id pub-id-type="pii">pharmaceuticals-18-00268-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Route to versatile quinoline-5,8-dione framework <bold>3</bold>.</p></caption><graphic xlink:href="pharmaceuticals-18-00268-sch001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00268-sch002"><object-id pub-id-type="pii">pharmaceuticals-18-00268-sch002_Scheme 2</object-id><label>Scheme 2</label><caption><p>C(7) substitution to furnish the phenoxy ether products.</p></caption><graphic xlink:href="pharmaceuticals-18-00268-sch002" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00268-f004"><label>Figure 4</label><caption><p>SphK assay with representative subset of 7-phenoxy quinoline-5,8-diones. Measurement of fluorescence intensity with excitation at 485 nm and emission at 535 nm reported as a percentage of negative control. Novel quinoline-5,8-diones and opaganib were incubated at 10 &#x003bc;M conc., PF-543 = 100 nM conc.</p></caption><graphic xlink:href="pharmaceuticals-18-00268-g004" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00268-f005"><label>Figure 5</label><caption><p>(<bold>A</bold>) Visualisation of sphingosine in lipid-binding site of SphK1 (PDB 3VZB); (<bold>B</bold>) PF-543 in ligand-binding site of SphK1. Areas of green represent H-bonding accepting sites, while areas of purple represent H-bonding donor sites (PDB 4V24) [<xref rid="B48-pharmaceuticals-18-00268" ref-type="bibr">48</xref>].</p></caption><graphic xlink:href="pharmaceuticals-18-00268-g005" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00268-sch003"><object-id pub-id-type="pii">pharmaceuticals-18-00268-sch003_Scheme 3</object-id><label>Scheme 3</label><caption><p>Incorporating the pyrrolidine headgroup into the quinoline-5,8-dione.</p></caption><graphic xlink:href="pharmaceuticals-18-00268-sch003" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00268-sch004"><object-id pub-id-type="pii">pharmaceuticals-18-00268-sch004_Scheme 4</object-id><label>Scheme 4</label><caption><p>Selenium dioxide oxidation to functionalise the C(2) position.</p></caption><graphic xlink:href="pharmaceuticals-18-00268-sch004" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00268-sch005"><object-id pub-id-type="pii">pharmaceuticals-18-00268-sch005_Scheme 5</object-id><label>Scheme 5</label><caption><p>Reductive amination to attach the pyrrolidine headgroup.</p></caption><graphic xlink:href="pharmaceuticals-18-00268-sch005" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00268-f006"><label>Figure 6</label><caption><p>SphK inhibitory assay with representative subset of 2-formyl and 2-pyrrolidinyl quinoline-5,8-diones. (2-substituted quinoline-5,8-diones incubated at 10 &#x003bc;M conc.).</p></caption><graphic xlink:href="pharmaceuticals-18-00268-g006" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00268-f007"><label>Figure 7</label><caption><p>SphK inhibition assay with two lead quinoline-5,8-diones <bold>4</bold> and <bold>20</bold>. (<bold>A</bold>) = SphK1 inhibition; (<bold>B</bold>) = SphK2 inhibition (IC<sub>50</sub> values in &#x000b5;M).</p></caption><graphic xlink:href="pharmaceuticals-18-00268-g007" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00268-f008"><label>Figure 8</label><caption><p>(<bold>A</bold>) Proposed interactions between fluoro analogue <bold>21</bold> and amino acid residues in the ligand-binding site of SphK1. (<bold>B</bold>) 2D representation of the 3D interactions described in (<bold>A</bold>). (green = hydrogen bond, pink = &#x003c0;-alkyl or alkyl, yellow = &#x003c0;-sulfur). (<bold>C</bold>) PF-543 in lipid-binding site. (<bold>D</bold>) PF-543 (blue) superimposed with <bold>21</bold> for docking comparison.</p></caption><graphic xlink:href="pharmaceuticals-18-00268-g008" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-18-00268-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00268-t001_Table 1</object-id><label>Table 1</label><caption><p>Pyrrolidine quinoline-5,8-dione <bold>21</bold> and precursor <bold>6</bold> docking scores within SphK1 ligand-binding site, with PF-543 as a docking reference. Negative scores correspond to a greater binding efficacy. ClogP was calculated using SwissADME [<xref rid="B56-pharmaceuticals-18-00268" ref-type="bibr">56</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Entry</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Score</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CLogP</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>PF-543</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;109.2</td><td align="center" valign="middle" rowspan="1" colspan="1">4.75</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>6</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;56.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.29</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>21</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;82.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.41</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00268-t002"><object-id pub-id-type="pii">pharmaceuticals-18-00268-t002_Table 2</object-id><label>Table 2</label><caption><p>NCI60 one-dose anticancer screen of compounds <bold>4</bold>&#x02013;<bold>7</bold> and <bold>12</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">4</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">5</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">6</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">7</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">12</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Mean Growth (%) <sup>1</sup></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.5</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Compounds screened against the NCI-60 cell line panel at 10 &#x003bc;M concentration, value given is the mean growth percentage across 60 cell lines.</p></fn></table-wrap-foot></table-wrap></sec></back></article>